PT72796B - Dispositif accione par osmose - Google Patents

Dispositif accione par osmose

Info

Publication number: PT72796B
Authority: PT; Portugal
Prior art keywords: active agent; compartment; dispensing; accordied; osmose
Prior art date: 1980-04-25

Application number

PT72796A

Other languages

English (en)

French (fr)

Portuguese (pt)

Other versions

PT72796A (fr

Inventor

Patrick Seck-Lai Wong

Felix Theeuwes

Pieter Bonsen

Original Assignee

Alza Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-04-25

Filing date

1981-04-02

Publication date

1982-03-30

1981-04-02 Application filed by Alza Corp filed Critical Alza Corp

1981-05-01 Publication of PT72796A publication Critical patent/PT72796A/pt

1982-03-30 Publication of PT72796B publication Critical patent/PT72796B/pt

Links

239000013543 active substance Substances 0.000 abstract 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 2
239000012530 fluid Substances 0.000 abstract 2
150000007514 bases Chemical class 0.000 abstract 1
229910002092 carbon dioxide Inorganic materials 0.000 abstract 1
239000001569 carbon dioxide Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
External Artificial Organs (AREA)
Separation Using Semi-Permeable Membranes (AREA)
Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)

PT72796A 1980-04-25 1981-04-02 Dispositif accione par osmose PT72796B (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/143,644 US4265874A (en)	1980-04-25	1980-04-25	Method of delivering drug with aid of effervescent activity generated in environment of use

Publications (2)

Publication Number	Publication Date
PT72796A PT72796A (fr)	1981-05-01
PT72796B true PT72796B (fr)	1982-03-30

Family

ID=22504961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT72796A PT72796B (fr)	1980-04-25	1981-04-02	Dispositif accione par osmose

Country Status (11)

Country	Link
US (1)	US4265874A (2)
EP (1)	EP0040899B1 (2)
JP (1)	JPS56167617A (2)
AT (1)	ATE9267T1 (2)
DE (1)	DE3165901D1 (2)
DK (1)	DK152482C (2)
ES (2)	ES267593Y (2)
GR (1)	GR73519B (2)
IE (1)	IE51216B1 (2)
NZ (1)	NZ196561A (2)
PT (1)	PT72796B (2)

Families Citing this family (747)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2470599A1 (fr) *	1979-12-07	1981-06-12	Panoz Donald	Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4344929A (en) *	1980-04-25	1982-08-17	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
JPS5770816A (en) *	1980-10-17	1982-05-01	Ono Pharmaceut Co Ltd	Multilayered film preparation of prostagladin of prolonged action
FR2525474A1 (fr) *	1982-04-26	1983-10-28	Roussel Uclaf	Nouvelle forme pharmaceutique orale de clometacine
US4478596A (en) *	1982-11-26	1984-10-23	Michelson Paul E	Delivery system for physiologically active agents
US4613330A (en) *	1982-11-26	1986-09-23	Michelson Paul E	Delivery system for desired agents
NZ206600A (en) *	1983-05-11	1987-01-23	Alza Corp	Osmotic drug delivery device
JPH075457B2 (ja) *	1983-08-16	1995-01-25	ザウエルカムフアウンデ−シヨンリミテツド	調節された方法による有効成分の放出を可能にする医薬組成物
US4670578A (en) *	1983-08-29	1987-06-02	Merck & Co., Inc.	Process for crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters
EP0137364A3 (en) *	1983-09-23	1986-10-22	Merck & Co. Inc.	Suppository form of an osmotic therapeutic system
US4627850A (en) *	1983-11-02	1986-12-09	Alza Corporation	Osmotic capsule
GB2150434B (en) *	1983-12-01	1987-11-04	Alza Corp	Constant rate release systems
GB2150830B (en) *	1983-12-05	1987-08-19	Alza Corp	Drug dispenser
US4725427A (en) *	1984-03-13	1988-02-16	Albion International, Inc.	Effervescent vitamin-mineral granule preparation
US4595583A (en) *	1984-03-19	1986-06-17	Alza Corporation	Delivery system controlled administration of beneficial agent to ruminants
US4717566A (en) *	1984-03-19	1988-01-05	Alza Corporation	Dosage system and method of using same
EP0166354B1 (en)	1984-06-26	1992-08-05	Merck & Co. Inc.	Benzofused lactam compounds and pharmaceutical compositions containing them
US4693895A (en) *	1984-10-26	1987-09-15	Alza Corporation	Colon delivery system
US4624847A (en) *	1985-04-22	1986-11-25	Alza Corporation	Drug delivery device for programmed delivery of beneficial drug
US4627971A (en) *	1985-04-22	1986-12-09	Alza Corporation	Osmotic device with self-sealing passageway
US4675174A (en) *	1985-08-16	1987-06-23	Alza Corporation	Veterinary dispenser delivering beneficial agent by gas power generated in situ
US4723957A (en) *	1986-02-07	1988-02-09	Alza Corp.	System for delivering drug with enhanced bioacceptability
US4971790A (en) *	1986-02-07	1990-11-20	Alza Corporation	Dosage form for lessening irritation of mocusa
US4662880A (en) *	1986-03-14	1987-05-05	Alza Corporation	Pseudoephedrine, brompheniramine therapy
US4753802A (en) *	1986-03-19	1988-06-28	Alza Corporation	Verapamil dosage form
US4847093A (en) *	1986-06-19	1989-07-11	Alza Corporation	Dosage form with means for governing rate of gas formation
US5143908A (en) *	1986-11-05	1992-09-01	Merck & Co., Inc.	Antibacterial agents and potentiators of carbapenem antibiotics
US4715994A (en) *	1986-11-05	1987-12-29	Merck & Co., Inc.	Novel antibacterial agents and potentiators of carbapenem antibiotics
US5099063A (en) *	1986-11-05	1992-03-24	Merck & Co., Inc.	Certain phosphinic acid derivatives having antibacterial activity
US5110597A (en) *	1987-06-25	1992-05-05	Alza Corporation	Multi-unit delivery system
US5023088A (en) *	1987-06-25	1991-06-11	Alza Corporation	Multi-unit delivery system
US5499979A (en) *	1987-06-25	1996-03-19	Alza Corporation	Delivery system comprising kinetic forces
US4874388A (en) *	1987-06-25	1989-10-17	Alza Corporation	Multi-layer delivery system
US4957494A (en) *	1987-06-25	1990-09-18	Alza Corporation	Multi-layer delivery system
US5938654A (en) *	1987-06-25	1999-08-17	Alza Corporation	Osmotic device for delayed delivery of agent
US5041644A (en) *	1987-07-06	1991-08-20	Merck & Co., Inc.	Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
JPS6413097A (en) *	1987-07-06	1989-01-17	Mitsubishi Chem Ind	Phosphonic acid derivative
DE3873278T2 (de)	1987-09-22	1993-02-25	Merck & Co Inc	Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren.
US5030732A (en) *	1988-03-03	1991-07-09	Merck & Co., Inc.	Aminoethylphosphinic acid derivatives
US5211957A (en) *	1988-03-25	1993-05-18	Ciba-Geigy Corporation	Solid rapidly disintegrating dosage form
CH675537A5 (2) *	1988-03-25	1990-10-15	Ciba Geigy Ag
US5147867A (en) *	1988-10-28	1992-09-15	Merck & Co., Inc.	Phosphorus containing enzyme inhibitors
US4962097A (en) *	1988-10-28	1990-10-09	Merck & Co., Inc.	Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
US5145990A (en) *	1988-10-28	1992-09-08	Merck & Co., Inc.	Phosphorous containing dhp enzyme inhibitors
US4942039A (en) *	1989-05-09	1990-07-17	Miles Inc.	Effervescent analgesic antacid composition having reduced sodium content
US5223264A (en) *	1989-10-02	1993-06-29	Cima Labs, Inc.	Pediatric effervescent dosage form
US5089530A (en)	1990-08-03	1992-02-18	Merck & Co., Inc.	Novel fermentation product with antiparasitic activity
US5443459A (en) *	1991-01-30	1995-08-22	Alza Corporation	Osmotic device for delayed delivery of agent
SG84487A1 (en)	1991-04-17	2001-11-20	Merck & Co Inc	Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US5198229A (en) *	1991-06-05	1993-03-30	Alza Corporation	Self-retaining gastrointestinal delivery device
US5223265A (en) *	1992-01-10	1993-06-29	Alza Corporation	Osmotic device with delayed activation of drug delivery
US5639782A (en) *	1992-03-04	1997-06-17	Center For Innovative Technology	Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
US5463083A (en)	1992-07-13	1995-10-31	Cytomed, Inc.	Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5434151A (en) *	1992-08-24	1995-07-18	Cytomed, Inc.	Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
HUT72601A (en)	1992-07-13	1996-05-28	Cytomed Inc	2,5-diaryl tetrahydro-thiophenes-furans and analogs for the treatment of inflammatory and immune disorders
US5498255A (en) *	1993-08-17	1996-03-12	Alza Corporation	Osmotic device for protracted pulsatile delivery of agent
US5403952A (en) *	1993-10-08	1995-04-04	Merck & Co., Inc.	Substituted cyclic derivatives as novel antidegenerative agents
US5703093A (en) *	1995-05-31	1997-12-30	Cytomed, Inc.	Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5792776A (en) *	1994-06-27	1998-08-11	Cytomed, Inc.,	Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5750565A (en)	1995-05-25	1998-05-12	Cytomed, Inc.	Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US6348571B1 (en)	1994-09-12	2002-02-19	Northwestern University	Corticotropin release inhibiting factor and methods of using same
US5767113A (en) *	1995-05-10	1998-06-16	The Salk Institute For Biological Studies	Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
US7048906B2 (en) *	1995-05-17	2006-05-23	Cedars-Sinai Medical Center	Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) *	1999-08-11	2005-03-01	Cedars-Sinai Medical Center	Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
JPH11505258A (ja) *	1995-05-17	1999-05-18	セダーシナイメディカルセンター	小腸における消化および吸収を改善させる脂肪酸を含む組成物
US6558708B1 (en)	1995-05-17	2003-05-06	Cedars-Sinai Medical Center	Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5817335A (en) *	1995-05-26	1998-10-06	Alza Corporation	Osmotic device with high drug loading and delayed activation of drug delivery
US5800422A (en) *	1995-06-02	1998-09-01	Alza Corporation	Osmotic device with delayed activation of drug delivery and complete drug release
US5756540A (en) *	1995-06-02	1998-05-26	Mcw Research Foundation, Inc.	Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5741815A (en) *	1995-06-02	1998-04-21	Lai; Ching-San	Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US6372713B1 (en)	1995-09-08	2002-04-16	The Board Of Trustees Of Northwestern University	Anti-depressant effects of corticotropin release inhibiting factor
US5747532A (en) *	1995-11-21	1998-05-05	Medinox, Inc.	Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6723531B2 (en)	1996-04-05	2004-04-20	The Salk Institute For Biological Studies	Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US5902605A (en) *	1996-04-18	1999-05-11	Alza Corporation	Drug delivery device with minimal residual drug retention
US5785688A (en) *	1996-05-07	1998-07-28	Ceramatec, Inc.	Fluid delivery apparatus and method
US5939460A (en) *	1996-07-08	1999-08-17	Idun Pharmaceuticals, Inc.	Method of inhibiting NADPH oxidase
US5677318A (en) *	1996-07-11	1997-10-14	Merck Frosst Canada, Inc.	Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5922761A (en) *	1996-09-06	1999-07-13	Medinox, Inc.	Methods for in vivo reduction of iron levels and compositions useful therefor
CA2265877A1 (en)	1996-09-10	1998-03-19	Medinox, Inc.	Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
US5858402A (en) *	1997-02-11	1999-01-12	Medinox, Inc.	Methods for in vivo reduction of cyanide levels and compositions useful therefor
US5916910A (en)	1997-06-04	1999-06-29	Medinox, Inc.	Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6294350B1 (en)	1997-06-05	2001-09-25	Dalhousie University	Methods for treating fibroproliferative diseases
US5985592A (en) *	1997-06-05	1999-11-16	Dalhousie University	Uses for pentoxifylline or functional derivatives/metabolites thereof
US5840721A (en) *	1997-07-09	1998-11-24	Ontogen Corporation	Imidazole derivatives as MDR modulators
US7105496B2 (en) *	1998-07-23	2006-09-12	Northwestern University	Methods and compositions for inhibiting angiogenesis
US6797691B1 (en) *	1997-07-23	2004-09-28	Northwestern University	Methods and compositions for inhibiting angiogenesis
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
WO1999019295A1 (en)	1997-10-10	1999-04-22	Trustees Of The University Of Pennsylvania	Compositions and methods for inhibiting arginase activity
WO1999018949A1 (en)	1997-10-15	1999-04-22	Thomas Jefferson University	Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US6750201B1 (en) *	1997-10-17	2004-06-15	The Trustees Of The University Of Pennsylvania	Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6984773B1 (en) *	1998-01-09	2006-01-10	The Salk Institute For Biological Studies	Transgenic mice expressing a human SXR receptor polypeptide
US6756491B2 (en)	1998-01-09	2004-06-29	The Salk Institute For Biological Studies	Steroid-activated nuclear receptors and uses therefor
WO1999047549A1 (en) *	1998-03-16	1999-09-23	Ontogen Corporation	PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
US6287605B1 (en) *	1998-04-17	2001-09-11	The Trustees Of The University Of Pennsylvania	Compositions and methods useful in treatment and prevention of HIV-1 infection
AU3979099A (en)	1998-05-11	1999-11-29	Philadelphia Health & Education Corporation	(mct-1), a human oncogene
US6333318B1 (en)	1998-05-14	2001-12-25	The Salk Institute For Biological Studies	Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US20030220258A1 (en) *	2001-12-21	2003-11-27	Robbert Benner	Treatment of ischemic events
US20050203187A1 (en) *	1998-06-01	2005-09-15	Verbiscar Anthony J.	Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
US6093743A (en) *	1998-06-23	2000-07-25	Medinox Inc.	Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6596770B2 (en)	2000-05-05	2003-07-22	Medinox, Inc.	Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6265420B1 (en)	1998-06-23	2001-07-24	Medinox, Inc.	Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US20030064917A1 (en) *	1998-07-23	2003-04-03	Crawford Susan E.	Methods and compositions for inhibiting angiogenesis
WO2000009118A1 (en)	1998-08-13	2000-02-24	The Wistar Institute	Methods for reducing atherosclerotic plaques
US6565854B2 (en)	1998-08-13	2003-05-20	Philadelphia Health And Education Corporation	Antimicrobial histone H1 compositions, kits, and methods of use thereof
US6646113B1 (en)	1998-09-17	2003-11-11	The Trustees Of The University Of Pennsylvania	Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US20020138856A1 (en) *	1998-10-23	2002-09-26	Northwestern University	Compositions and methods useful for treatment of depressive disorder based on an animal model
DK1140198T3 (da)	1999-01-13	2008-03-10	Alchemia Oncology Pty Ltd	Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
US6395029B1 (en)	1999-01-19	2002-05-28	The Children's Hospital Of Philadelphia	Sustained delivery of polyionic bioactive agents
US6852704B1 (en)	1999-01-19	2005-02-08	The Children's Hospital Of Philadelphia	Reverse gene therapy
US7282489B2 (en) *	2000-01-19	2007-10-16	The Children's Hospital Of Philadelphia	Compositions and methods for performing reverse gene therapy
AU764005B2 (en)	1999-02-25	2003-08-07	Merck Frosst Canada & Co.	PDE IV inhibiting compounds, compositions and methods of treatment
US7141417B1 (en) *	1999-02-25	2006-11-28	Thomas Jefferson University	Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
US6221855B1 (en)	1999-03-11	2001-04-24	Wake Forest University	Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
US6428968B1 (en)	1999-03-15	2002-08-06	The Trustees Of The University Of Pennsylvania	Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6025502A (en) *	1999-03-19	2000-02-15	The Trustees Of The University Of Pennsylvania	Enantopselective synthesis of methyl phenidate
US6251927B1 (en)	1999-04-20	2001-06-26	Medinox, Inc.	Methods for treatment of sickle cell anemia
AU4803800A (en)	1999-04-27	2000-11-10	Trustees Of The University Of Pennsylvania, The	Compositions, methods, and kits relating to LTiGTresistinLT/iGT
US6420545B1 (en) *	1999-05-24	2002-07-16	The Trustees Of The University Of Pennsylvania	CD4-independent HIV envelope proteins as vaccines and therapeutics
US7160694B2 (en)	1999-06-14	2007-01-09	Millennium Pharmaceuticals, Inc.	Nucleic acids encoding TANGO405 and functional fragments and uses thereof
US7033780B1 (en) *	1999-06-14	2006-04-25	Millennium Pharmaceuticals, Inc.	Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US6964854B1 (en)	1999-07-13	2005-11-15	Science & Technology Corporation	Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
EP2064951A1 (en)	1999-10-08	2009-06-03	Taiji Biomedical, Inc.	Use of a substituted imidazole, derivatives or salts thereof for the preparation of a medicament for the treatment of a cell proliferative disorder
US20020147197A1 (en) *	1999-10-08	2002-10-10	Newman Michael J.	Methods and compositions for enhancing pharmaceutical treatments
JP4754143B2 (ja)	1999-10-12	2011-08-24	ケモセントリックス，インコーポレイテッド	ケモカインレセプター
US6274627B1 (en)	1999-10-12	2001-08-14	Medinox, Inc.	Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
US7057015B1 (en)	1999-10-20	2006-06-06	The Salk Institute For Biological Studies	Hormone receptor functional dimers and methods of their use
JP3417370B2 (ja)	1999-12-09	2003-06-16	株式会社村田製作所	非可逆回路素子及び通信機装置
US6559128B1 (en)	2000-01-21	2003-05-06	Northwestern University	Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US20030212021A1 (en) *	2001-01-25	2003-11-13	Frost Gregory I.	Myeloid colony stimulating factor and uses thereof
US6464688B1 (en)	2000-02-15	2002-10-15	Microsolutions, Inc.	Osmotic pump delivery system with flexible drug compartment
JP2001320205A (ja)	2000-03-02	2001-11-16	Murata Mfg Co Ltd	非可逆回路素子および通信装置
US7358330B2 (en) *	2001-03-29	2008-04-15	Biotempt B.V.	Immunoregulatory compositions
US6509315B1 (en)	2000-04-07	2003-01-21	The Trustees Of The University Of Pennsylvania	Didemnin analogs and fragments and methods of making and using them
ES2272462T3 (es) *	2000-04-07	2007-05-01	The Trustees Of The University Of Pennsylvania	Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
AU778368B2 (en) *	2000-05-15	2004-12-02	Darwin Discovery Limited	Hydroxamic acid derivatives
US6613801B2 (en) *	2000-05-30	2003-09-02	Transtech Pharma, Inc.	Method for the synthesis of compounds of formula I and their uses thereof
US7087632B2 (en) *	2001-03-05	2006-08-08	Transtech Pharma, Inc.	Benzimidazole derivatives as therapeutic agents
US6908741B1 (en)	2000-05-30	2005-06-21	Transtech Pharma, Inc.	Methods to identify compounds that modulate RAGE
AU2001275043A1 (en)	2000-05-31	2001-12-11	Drugtech Corporation	Mineral supplement
WO2001097752A2 (en) *	2000-06-20	2001-12-27	The Trustees Of The University Of Pennsylvania	Compositions comprising urokinase for modulating muscle contractility and angiogenisis
US6429223B1 (en)	2000-06-23	2002-08-06	Medinox, Inc.	Modified forms of pharmacologically active agents and uses therefor
US9066919B2 (en) *	2000-07-14	2015-06-30	Alchemia Oncology Pty Limited	Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) *	2000-07-14	2000-08-10	Meditech Research Limited	Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
ES2340662T3 (es)	2000-07-19	2010-06-08	Advanced Research And Technology Institute	Factor de crecimiento de fibroblastos (fgf23) nuevo procedimiento para el uso.
WO2002019965A2 (en) *	2000-09-07	2002-03-14	Science & Technology Corporation @ Unm	Heat shock response and virus replication
WO2002026240A2 (en) *	2000-09-26	2002-04-04	Sidney Kimmel Cancer Center	Inhibition of antigen presentation with poorly catabolized polymers
US20040102367A1 (en) *	2001-02-23	2004-05-27	Gage Fred H	Gene expression system based on chimeric receptors
CN1494425B (zh) *	2001-03-05	2011-12-07	特兰斯泰克制药公司	用作治疗剂的羧酰胺衍生物
WO2002070667A2 (en) *	2001-03-05	2002-09-12	Transtech Pharma, Inc.	High level insect expression of rage proteins
US7208279B2 (en) *	2001-03-14	2007-04-24	Caden Biosciences, Inc.	Method for identifying inhibitors of G protein coupled receptor signaling
US7294472B2 (en) *	2001-03-14	2007-11-13	Caden Biosciences	Method for identifying modulators of G protein coupled receptor signaling
ITMI20010733A1 (it)	2001-04-05	2002-10-05	Recordati Chem Pharm	Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6727287B2 (en)	2001-04-16	2004-04-27	Pts International, Inc.	Toluene sulfonamide-containing anti-tumor composition and method of use thereof
US6632217B2 (en)	2001-04-19	2003-10-14	Microsolutions, Inc.	Implantable osmotic pump
CN1157388C (zh) *	2001-05-29	2004-07-14	北京大学	哌嗪基二硫代甲酸酯类化合物,它们的制备方法和在抗肿瘤药物中的应用
RU2259825C9 (ru)	2001-06-18	2006-04-10	БиоДием Лимитед	Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6884619B2 (en)	2001-07-17	2005-04-26	Yale University	Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US20030082720A1 (en) *	2001-07-17	2003-05-01	Lifton Richard P.	Compositions methods and kits relating to treating and diagnosing hypertension
GB0119396D0 (en) *	2001-08-09	2001-10-03	Celltech R&D Ltd	Hydroxamic acid derivatives
CA2456977C (en) *	2001-08-16	2011-06-07	The Trustees Of The University Of Pennsylvania	Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
US9056048B2 (en) *	2001-08-16	2015-06-16	The Trustees Of The University Of Pennsylvania	Synthesis and use of cationic steroids for anti-inflammatory drug therapy
CA2458856C (en) *	2001-08-27	2011-02-15	Meditech Research Limited	Improved therapeutic protocols
US20030069071A1 (en) *	2001-09-28	2003-04-10	Tim Britt	Entertainment monitoring system and method
US7141648B2 (en) *	2001-10-19	2006-11-28	Isotechnika Inc.	Synthesis of cyclosporin analogs
US6555563B1 (en)	2001-11-16	2003-04-29	Medinox, Inc.	Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
US7871619B2 (en) *	2001-11-30	2011-01-18	Chemocentryx, Inc.	Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) *	2001-11-30	2008-08-19	Chemocentryx, Inc.	Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) *	2001-11-30	2007-08-07	Chemocentryx, Inc.	Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) *	2001-11-30	2008-10-28	Chemocentryx, Inc.	Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
PE20030701A1 (es) *	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
WO2003055482A1 (en)	2001-12-21	2003-07-10	Novo Nordisk A/S	Amide derivatives as gk activators
AR038136A1 (es)	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US20030161882A1 (en) *	2002-02-01	2003-08-28	Waterman Kenneth C.	Osmotic delivery system
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
US20030175346A1 (en) *	2002-02-01	2003-09-18	Anne Billotte	Osmotic delivery system
US7378111B2 (en) *	2002-02-20	2008-05-27	The Trustees Of The University Of Pennsylvania	Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
JP4481011B2 (ja) *	2002-03-05	2010-06-16	トランステックファーマ，インコーポレイテッド	リガンドのｒａｇｅとの相互作用を阻害する単環式および二環式アゾール誘導体
DE60335869D1 (de)	2002-04-11	2011-03-10	Merck Sharp & Dohme	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
US7622117B2 (en) *	2002-04-17	2009-11-24	Dynamis Therapeutics, Inc.	3-deoxyglucosone and skin
DE60302454T2 (de) *	2002-04-19	2006-08-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
US20030232741A1 (en) *	2002-05-06	2003-12-18	Washington University	Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
US20080051428A1 (en) *	2002-05-15	2008-02-28	Davis Paul J	Pyrroloquinoline quinone drugs and methods of use thereof
AUPS234402A0 (en) *	2002-05-15	2002-06-13	Auckland Uniservices Limited	Anti-tumour polycyclic carboxamides
EP2399903A1 (en)	2002-05-24	2011-12-28	Millennium Pharmaceuticals, Inc.	Ccr9 inhibitors and methods of use thereof
US7842693B2 (en) *	2002-06-12	2010-11-30	Chemocentryx, Inc.	Substituted piperazines
US6727241B2 (en)	2002-06-12	2004-04-27	Chemocentryx	Anti-inflammatory compositions and methods of use
US20050256130A1 (en) *	2002-06-12	2005-11-17	Chemocentryx, Inc.	Substituted piperazines
US7589199B2 (en)	2002-06-12	2009-09-15	Chemocentryx, Inc.	Substituted piperazines
DK1531822T3 (da)	2002-06-12	2009-12-07	Chemocentryx Inc	1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US20040077691A1 (en) *	2002-06-21	2004-04-22	Medinox, Inc.	Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
US6620813B1 (en)	2002-06-21	2003-09-16	Medinox, Inc.	Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
BR0312023A (pt)	2002-06-27	2005-03-22	Novo Nordisk As	Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
MXPA05003607A (es)	2002-10-04	2005-11-17	Prana Biotechnology Ltd	Compuestos neurologicamente activos.
WO2004037206A2 (en) *	2002-10-23	2004-05-06	University Of Hawaii	Methods for diagnosing and treating pre-term labor
US20060247216A1 (en) *	2002-10-25	2006-11-02	Haj-Yehia Abdullah I	Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
WO2004041279A1 (en)	2002-10-30	2004-05-21	Merck & Co., Inc.	Gamma-aminoamide modulators of chemokine receptor activity
ATE468114T1 (de)	2002-11-08	2010-06-15	High Point Pharmaceuticals Llc	Sichere chemische entkuppler zur behandlung von fettsucht
US20050143449A1 (en) *	2002-11-15	2005-06-30	The Salk Institute For Biological Studies	Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7420055B2 (en) *	2002-11-18	2008-09-02	Chemocentryx, Inc.	Aryl sulfonamides
US7741519B2 (en)	2007-04-23	2010-06-22	Chemocentryx, Inc.	Bis-aryl sulfonamides
US6939885B2 (en)	2002-11-18	2005-09-06	Chemocentryx	Aryl sulfonamides
US20070021466A1 (en) *	2002-11-18	2007-01-25	Solomon Ungashe	CCR2 inhibitors and methods of use thereof
US7227035B2 (en) *	2002-11-18	2007-06-05	Chemocentryx	Bis-aryl sulfonamides
KR100772297B1 (ko) *	2002-11-22	2007-11-02	니뽄 다바코 산교 가부시키가이샤	융합 비시클릭 질소-함유 헤테로사이클
US20060166894A1 (en) *	2002-11-29	2006-07-27	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Ace-inhibitors having antioxidant and no-donor activity
AU2003295171B2 (en)	2002-12-20	2007-09-06	Arakis Ltd.	Benzoxazocines and their use as monoamine-reuptake inhibitors
ATE427933T1 (de) *	2002-12-20	2009-04-15	Chemocentryx Inc	Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
US8337861B2 (en) *	2003-01-09	2012-12-25	The Trustees Of The University Of Pennsylvania	Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
AU2003900927A0 (en) *	2003-02-28	2003-03-13	Biodiem Ltd	Growth promotion method
CA2519234A1 (en) *	2003-03-21	2004-10-07	Madeleine M. Joullie	Tamandarin analogs and fragments thereof and methods of making and using
ATE467616T1 (de)	2003-04-11	2010-05-15	High Point Pharmaceuticals Llc	Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
JO2355B1 (en)	2003-04-15	2006-12-12	ميرك شارب اند دوم كوربوريشن	Hereditary calcitonin polypeptide receptor antagonists
US8158149B2 (en) *	2004-05-12	2012-04-17	Chelsea Therapeutics, Inc.	Threo-DOPS controlled release formulation
WO2004100929A1 (en)	2003-05-12	2004-11-25	Synergia Pharma, Inc.	Threo-dops controlled release formulation
AR041089A1 (es)	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EP1635823A1 (en) *	2003-05-20	2006-03-22	TransTech Pharma Inc.	Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
BRPI0413018B8 (pt) *	2003-07-30	2021-05-25	Rigel Pharmaceuticals Inc	composto, e, uso de um composto
EP1653969A4 (en) *	2003-08-07	2006-12-20	Japan Tobacco Inc	PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
WO2005014028A1 (en)	2003-08-08	2005-02-17	Novo Nordisk A/S	Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
WO2005025513A2 (en) *	2003-09-12	2005-03-24	The Regents Of The Univeristy Of California	Guanidinium derivatives for improved cellular transport
WO2005033297A1 (en) *	2003-09-19	2005-04-14	The Rockefeller University	Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
EP1670815A2 (en)	2003-09-30	2006-06-21	Novo Nordisk A/S	Melanocortin receptor agonists
EP2633866A3 (en)	2003-10-17	2013-12-18	Novo Nordisk A/S	Combination therapy
US20100247540A1 (en) *	2003-10-30	2010-09-30	Chemocentryx, Inc.	Methods and Compositions For Modulating Angiogenesis
US20060018970A1 (en) *	2003-12-12	2006-01-26	Myogen, Inc.	Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
BRPI0417407A (pt) *	2003-12-15	2007-04-03	Theramex	derivados de 1-n-fenil-amino-1h-imidazol e composições farmacêuticas contendo estes
JP4834840B2 (ja)	2004-01-06	2011-12-14	ノヴォノルディスクアー／エス	ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
US7435831B2 (en) *	2004-03-03	2008-10-14	Chemocentryx, Inc.	Bicyclic and bridged nitrogen heterocycles
US7435830B2 (en) *	2004-03-03	2008-10-14	Chemocentryx, Inc.	Bicyclic and bridged nitrogen heterocycles
US20060003020A1 (en) *	2004-03-11	2006-01-05	The Regents Of The University Of Michigan	Anti-metastatic ability of mibefradil and gadolinium
CA2559211A1 (en)	2004-03-19	2005-09-29	Yale University	Detection, isolation and uses of renalase (monoamine oxidase c)
CA2560538A1 (en) *	2004-03-22	2005-10-06	Myogen, Inc.	(r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
EP1737448A1 (en) *	2004-03-22	2007-01-03	Myogen, Inc.	(s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
US7169807B2 (en) *	2004-04-09	2007-01-30	Allergan, Inc.	10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
NZ551775A (en) *	2004-06-01	2010-12-24	Univ Virginia	Dual small molecule inhibitors of cancer and angiogenesis
RU2007101074A (ru)	2004-06-14	2008-07-20	Зозер Б. САЛАМА (DE)	Фармацевтическая противораковая композиция пролина или его производных и противоопухолевого антитела
US8007814B2 (en)	2004-06-16	2011-08-30	University Of Massachusetts	Therapy for lysosomal enzyme deficiencies
US7740861B2 (en)	2004-06-16	2010-06-22	University Of Massachusetts	Drug delivery product and methods
EP1776108A1 (en) *	2004-06-23	2007-04-25	Myogen, Inc.	Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US8507411B2 (en) *	2004-06-24	2013-08-13	Wisconsin Alumni Research Foundation	Neoglycorandomization and digitoxin analogs
WO2006002381A1 (en) *	2004-06-24	2006-01-05	Wisconsin Alumni Research Foundation	Neoglycorandomization and digitoxin analogs
EP1765785B1 (en) *	2004-07-02	2009-07-08	Allergan, Inc.	Prostaglandin analogs
KR20070057818A (ko) *	2004-08-03	2007-06-07	트랜스테크 파르마, 인크.	Ｒａｇｅ 융합 단백질 및 이의 사용 방법
US7183310B2 (en) *	2004-08-10	2007-02-27	Allergan, Inc.	Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) *	2004-08-10	2006-09-05	Allergan, Inc.	Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7906552B2 (en)	2004-08-10	2011-03-15	Allergan, Inc.	Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO2006137839A2 (en)	2004-08-24	2006-12-28	Merck & Co., Inc.	Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
EP1796675A4 (en) *	2004-10-01	2009-03-04	Merck & Co Inc	COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
EP1647549A1 (en)	2004-10-14	2006-04-19	Laboratoire Theramex	Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
US7612082B2 (en) *	2004-10-28	2009-11-03	Allergan, Inc.	Prostaglandin EP4 antagonists
US7101906B2 (en) *	2004-11-16	2006-09-05	Allergan, Inc.	2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en)	2004-11-23	2007-02-27	Allergan, Inc.	2,3,4-substituted cyclopentanones as therapeutic agents
CN101137631A (zh)	2004-12-03	2008-03-05	转化技术制药公司	杂芳族葡糖激酶激活剂
US7091231B2 (en) *	2004-12-10	2006-08-15	Allergan, Inc.	12-Aryl prostaglandin analogs
CN101098700A (zh) *	2005-01-06	2008-01-02	默克公司	治疗炎性疾病的药物组合疗法和药用组合物
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7622583B2 (en)	2005-01-14	2009-11-24	Chemocentryx, Inc.	Heteroaryl sulfonamides and CCR2
ES2440965T3 (es)	2005-01-14	2014-01-31	Chemocentryx, Inc.	Heteroaril-sulfonamidas y CCR2
TWI386208B (zh) *	2005-04-18	2013-02-21	Allergan Inc	治療性的經取代環戊酮
WO2006116319A2 (en) *	2005-04-21	2006-11-02	Chemocentryx, Inc.	Reagents that bind ccx-ckr2
JP5774264B2 (ja)	2005-04-27	2015-09-09	アリーナファーマシューティカルズ，インコーポレイテッド	肥満および糖尿病、ならびにそれらに関連する病態の処置のため、ならびに血中ｇｌｐ−１レベルを増大させることによって緩和される病態の処置のための、併用療法
BRPI0611257A2 (pt) *	2005-05-06	2010-08-24	Allergan Inc	beta-lactamas substituÍdas e uso em medicina do mesmo
EP1721615A1 (en)	2005-05-09	2006-11-15	Komipharm International Co., Ltd.	Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
WO2006127361A2 (en)	2005-05-23	2006-11-30	Sdg, Inc.	Lipid construct for delivery of insulin to a mammal
US20070203161A1 (en) *	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en)	2005-06-08	2006-12-14	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
TW200716140A (en) *	2005-06-17	2007-05-01	Dynamis Therapeutics Inc	Treatment of inflammatory conditions
US7777035B2 (en)	2005-06-22	2010-08-17	Chemocentryx, Inc.	Azaindazole compounds and methods of use
CA2612585A1 (en)	2005-06-27	2007-01-04	Amgen Inc.	Anti-inflammatory aryl nitrile compounds
US8039507B2 (en) *	2005-06-29	2011-10-18	Allergan, Inc.	Therapeutic substituted gamma lactams
US7884210B2 (en)	2005-07-14	2011-02-08	Novo Nordisk A/S	Ureido-thiazole glucokinase activators
JP5465431B2 (ja) *	2005-07-27	2014-04-09	アルケミアオンコロジーピーティーワイリミテッド	ヒアルロナンを用いる治療プロトコル
US7879997B2 (en)	2005-08-12	2011-02-01	Schering Corporation	Compounds for the treatment of inflammatory disorders
EP2267030A1 (en)	2005-08-25	2010-12-29	Repair Technologies, Inc.	Devices, compositions and methods for the protection and repair of cells and tissues
JP5259408B2 (ja)	2005-08-29	2013-08-07	ユニバーシティオブバージニアパテントファンデーション	リソフィリン類縁体とその使用方法
US8871764B2 (en)	2005-08-29	2014-10-28	University Of Virginia Patent Foundation	Lisofylline analogs and methods for use
US20130131007A1 (en)	2005-09-07	2013-05-23	Bebaas, Inc.	Vitamin b12 compositions
WO2007028196A1 (en)	2005-09-07	2007-03-15	Alchemia Oncology Pty Limited	Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US20070178141A1 (en) *	2005-09-07	2007-08-02	Bebaas, Inc.	Vitamin B12 compositions
CA2626394A1 (en) *	2005-10-24	2007-05-03	University Of Massachusetts	Yeast cell wall particle for delivering osteoprotegerin-encoding polynucleotide
WO2007056457A2 (en)	2005-11-09	2007-05-18	Combinatorx, Incorporated	Methods, compositions, and kits for the treatment of medical conditions
DE602006018057D1 (de)	2005-11-10	2010-12-16	Chemocentryx Inc	Substituierte chinolone und verwendungsverfahren
US7585895B2 (en) *	2005-12-06	2009-09-08	Allergan, Inc.	Therapeutic substituted cyclopentanes
US7427685B2 (en)	2005-12-06	2008-09-23	Allergan, Inc.	Therapeutic substituted cyclopentanes
JP2009520833A (ja) *	2005-12-20	2009-05-28	ギリード・コロラド・インコーポレーテッド	４，７−ジヒドロチエノ［２，３−ｂ］ピリジン化合物及び医薬組成物
US7323477B2 (en) *	2006-02-02	2008-01-29	Allergan, Inc.	7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
US20070254047A1 (en) *	2006-02-21	2007-11-01	Astrum Therapeutics Pty Ltd	Compositions to reduce blood glucose levels and treat diabetes
CA2642229C (en)	2006-02-24	2015-05-12	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
EP1864692A1 (en) *	2006-06-07	2007-12-12	Biotempt B.V.	Use of peptides for the control of radiation injury
WO2007109578A2 (en)	2006-03-20	2007-09-27	Allergan, Inc.	Substituted gamma lactams as prostaglandin ep2 agonists
US20070225246A1 (en) *	2006-03-27	2007-09-27	Denu John M	O-acetyl-ADP-ribose non-hydrolyzable analogs
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
SG10201404220TA (en)	2006-04-11	2014-10-30	Arena Pharm Inc	Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
KR20080109096A (ko)	2006-04-14	2008-12-16	프라나 바이오테크놀로지 리미티드	연령 관련 황반 변성（에이엠디）의 치료 방법
US20090016981A1 (en)	2006-05-03	2009-01-15	Allergan, Inc.	Therapeutic compounds
US7439372B2 (en)	2006-05-03	2008-10-21	Allergan, Inc.	Therapeutic compounds
US7476755B2 (en)	2006-05-04	2009-01-13	Allergan, Inc.	Therapeutic compounds
CA2650932C (en)	2006-05-09	2013-01-22	Merck & Co., Inc.	Substituted spirocyclic cgrp receptor antagonists
US7547727B2 (en)	2006-05-22	2009-06-16	Allergan, Inc.	Therapeutic cyclopentane derivatives
US7550448B2 (en) *	2006-05-24	2009-06-23	Allergan, Inc.	Therapeutic compounds
US7553860B2 (en) *	2006-06-14	2009-06-30	Allergan, Inc.	Substituted gamma lactams as therapeutic agents
EP2465851A1 (en)	2006-07-05	2012-06-20	Aventis Agriculture	1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
WO2008008700A2 (en)	2006-07-10	2008-01-17	Allergan, Inc.	Substituted cyclopentane derivatives as therapeutic agents
US8519135B2 (en) *	2006-07-14	2013-08-27	Chemocentryx, Inc.	Heteroaryl sulfonamides and CCR2/CCR9
MX2009000395A (es)	2006-07-14	2009-01-29	Chemocentryx Inc	Triazolil fenil bencenosulfonamidas.
US7700627B2 (en) *	2006-07-26	2010-04-20	Allergan, Inc.	Therapeutic substituted lactams
JP5322935B2 (ja)	2006-07-31	2013-10-23	アクティベサイトファーマシューティカルズインコーポレイティッド	血漿カリクレインの阻害薬
US7985767B2 (en) *	2006-09-06	2011-07-26	Allergan, Inc.	Therapeutic amides
AU2007292816B2 (en)	2006-09-07	2011-11-17	Amgen Inc.	Benzo-fused compounds for use in treating metabolic disorders
US8232254B2 (en) *	2006-10-06	2012-07-31	Wisconsin Alumni Research Foundation	Colchicine neoglycosides and methods for their synthesis and use
EP2079728B1 (en)	2006-10-10	2013-09-25	Amgen Inc.	N-aryl pyrazole compounds for use against diabetes
EP1920781B1 (en)	2006-11-10	2015-03-04	Glycotope GmbH	Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
WO2008073752A2 (en)	2006-12-11	2008-06-19	Allergan, Inc.	Cyclobutyl derivatives for the treatment of glaucoma
GB0624757D0 (en)	2006-12-12	2007-01-17	Sosei R & D Ltd	Novel compounds
JP2010513569A (ja)	2006-12-19	2010-04-30	ユニバーシティオブバージニアパテントファウンデーション	アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
US20080153881A1 (en) *	2006-12-22	2008-06-26	Allergan, Inc.	Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153927A1 (en) *	2006-12-22	2008-06-26	Allergan, Inc.	Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20120083508A1 (en)	2006-12-22	2012-04-05	Allergan, Inc.	Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20100016355A1 (en)	2006-12-22	2010-01-21	Gil Daniel W	Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153874A1 (en) *	2006-12-22	2008-06-26	Allergan Inc.	Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153832A1 (en) *	2006-12-22	2008-06-26	Allergan, Inc.	Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153880A1 (en) *	2006-12-22	2008-06-26	Allergan, Inc.	Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153808A1 (en) *	2006-12-22	2008-06-26	Allergan, Inc.	Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153825A1 (en) *	2006-12-22	2008-06-26	Allergan Inc.	Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
EP2097689A1 (en) *	2006-12-28	2009-09-09	LG Electronics Inc.	Ice making system and method for ice making of refrigerator
WO2008084044A1 (en)	2007-01-11	2008-07-17	Novo Nordisk A/S	Urea glucokinase activators
WO2008101060A1 (en) *	2007-02-14	2008-08-21	Logical Therapeutics, Inc.	Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
CA2679301C (en)	2007-02-28	2015-08-11	University Of Virginia Patent Foundation	Lisofylline analogs and methods for use in protecting pancreatic .beta.-cells, treating type 1 diabetes, and treating inflammatory and autoimmune diseases
US8563594B2 (en) *	2007-05-08	2013-10-22	Allergan, Inc.	S1P3 receptor inhibitors for treating pain
RS55271B1 (sr)	2007-05-15	2017-02-28	Merial Sas	Ariloazol-2-il cijanoetilamino jedinjenja, postupci dobijanja i postupci njihove primene
DK2155712T3 (en)	2007-05-22	2016-12-19	Chemocentryx Inc	3- (imidazolyl) pyrazolo [3,4-b] pyridines
EP2546232A1 (en)	2007-06-20	2013-01-16	Merck Sharp & Dohme Corp.	Diphenyl Substituted Alkanes
US7776877B2 (en)	2007-06-22	2010-08-17	Chemocentryx, Inc.	N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
PL2175859T3 (pl)	2007-07-12	2012-09-28	Chemocentryx Inc	Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
US20100221334A1 (en) *	2007-07-19	2010-09-02	Fink Mitchell P	Compositions including leukotriene antagonists and nsaids and methods of using the same
US8222254B2 (en)	2007-08-07	2012-07-17	Prosarix Limited	1, 2, 4-triazole derivatives as serotonergic modulators
US8962015B2 (en)	2007-09-28	2015-02-24	Sdg, Inc.	Orally bioavailable lipid-based constructs
US8846053B2 (en)	2008-09-26	2014-09-30	Sdg, Inc.	Orally bioavailable lipid-based constructs
EP2205072B1 (en)	2007-10-15	2013-11-20	The Salk Institute for Biological Studies	Methods for treating a variety of diseases and conditions, and compounds useful therefor
WO2009052072A1 (en) *	2007-10-18	2009-04-23	Allergan, Inc.	Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2009052073A2 (en) *	2007-10-18	2009-04-23	Allergan, Inc.	Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20110160265A1 (en) *	2007-10-18	2011-06-30	Luhrs Lauren M B	Method of treating motor disorders with alpha-2b adrenergic receptor agonists
JP2011517279A (ja) *	2007-10-29	2011-06-02	ユニバーシティオブマサチューセッツ	核酸（ｓｉＲＮＡ）送達用の酵母細胞壁粒子（ＹＣＷＰ）多層状ナノ粒子
US8063033B2 (en)	2008-01-18	2011-11-22	Allergan, Inc.	Therapeutic beta-lactams
US7956051B2 (en) *	2008-01-24	2011-06-07	Allergan, Inc.	Therapeutic amides and related compounds
US8633310B2 (en) *	2008-02-19	2014-01-21	Allergan, Inc.	Therapeutic substituted lactams
US8202855B2 (en)	2008-03-04	2012-06-19	Allergan, Inc	Substituted beta-lactams
US7964596B2 (en) *	2008-03-07	2011-06-21	Allergan, Inc.	Therapeutic compounds
US20090233921A1 (en) *	2008-03-11	2009-09-17	Allergan, Inc.	Therapeutic cyclopentane derivatives
US7960379B2 (en) *	2008-03-14	2011-06-14	Allergan, Inc.	Therapeutic compounds
WO2009117335A2 (en) *	2008-03-17	2009-09-24	Allergan, Inc.	S1p3 receptor inhibitors for treating inflammation
US7732443B2 (en) *	2008-03-18	2010-06-08	Yariv Donde	Therapeutic substituted cyclopentanes
US7705001B2 (en) *	2008-03-18	2010-04-27	Allergan, Inc	Therapeutic substituted gamma lactams
US8198318B2 (en) *	2008-03-18	2012-06-12	Allergen, Inc.	Therapeutic amides
US7960378B2 (en) *	2008-03-18	2011-06-14	Allergan, Inc.	Therapeutic compounds
US7956055B2 (en) *	2008-03-25	2011-06-07	Allergan, Inc.	Substituted gamma lactams as therapeutic agents
EP2108960A1 (en)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
US8236838B2 (en) *	2008-04-21	2012-08-07	Institute For Oneworld Health	Compounds, compositions and methods comprising isoxazole derivatives
US20090264433A1 (en) *	2008-04-21	2009-10-22	Institute For Oneworld Health	Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131947A2 (en) *	2008-04-21	2009-10-29	Institute For Oneworld Health	Compounds, compositions and methods comprising pyridazine derivatives
US8207205B2 (en) *	2008-04-21	2012-06-26	Institute For Oneworld Health	Compounds, compositions and methods comprising oxadiazole derivatives
US7737140B2 (en) *	2008-04-24	2010-06-15	Allergan, Inc.	Therapeutic compounds
US7964634B2 (en) *	2008-04-24	2011-06-21	Allergan, Inc.	Therapeutic compounds
MY150518A (en) *	2008-04-24	2014-01-30	Allergan Inc	Substituted gamma lactams as therapeutic agents
EP2297084A1 (en) *	2008-04-24	2011-03-23	Allergan, Inc.	Therapeutic compounds
AU2009239381A1 (en)	2008-04-24	2009-10-29	Allergan, Inc.	Substituted gamma lactams as therapeutic agents
WO2009137345A1 (en) *	2008-05-09	2009-11-12	Allergan, Inc.	Therapeutic compounds
CA2728227A1 (en) *	2008-05-09	2009-11-12	Allergan, Inc.	Therapeutic cyclopentane derivatives
RU2010149494A (ru) *	2008-05-09	2012-06-20	Аллерган, Инк. (Us)	Терапевтические замещенные тиазолидиноны, оксазолидиноны и родственные соединения
EP2300439A1 (en)	2008-05-09	2011-03-30	Allergan, Inc.	Therapeutic substituted hydantoins, and related compounds
US7981887B2 (en) *	2008-05-09	2011-07-19	Allergan, Inc.	Therapeutic compounds
JP2011519937A (ja) *	2008-05-09	2011-07-14	アラーガンインコーポレイテッド	治療用ｎ‐アリールまたはｎ‐ヘテロアリールピラゾリジンおよびピラゾリジノン誘導体
WO2009137412A1 (en) *	2008-05-09	2009-11-12	Allergan, Inc.	Therapeutic compounds
US8252788B2 (en) *	2008-05-20	2012-08-28	Allergan, Inc.	Therapeutic compounds
US8124648B2 (en) *	2008-05-20	2012-02-28	Allergan, Inc.	Therapeutic lactams
EP2300412A1 (en) *	2008-05-27	2011-03-30	Allergan, Inc.	Prostaglandin produgs as hypotensive agents
JP2011523958A (ja)	2008-06-12	2011-08-25	メルク・シャープ・エンド・ドーム・コーポレイション	Ｃｇｒｐ受容体アンタゴニストとしての分岐状３−及び６−置換キノリン
US20100022574A1 (en) *	2008-07-28	2010-01-28	EndogenX, Inc.	Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US8586607B2 (en)	2008-07-28	2013-11-19	Syddansk Universitet	Compounds for the treatment of metabolic diseases
WO2010019796A1 (en)	2008-08-14	2010-02-18	Chemietek, Llc	Heterocyclic amide derivatives as ep4 receptor antagonists
US20110237528A1 (en) *	2008-09-19	2011-09-29	Institute For Oneworld Health	Compositions and methods comprising imidazole and triazole derivatives
JO2870B1 (en)	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
EP2186521A1 (en)	2008-11-14	2010-05-19	Mergemeier Steffen	Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
AR074024A1 (es)	2008-11-14	2010-12-15	Merial Ltd	Compuesto de arilazol-2-il-cianoetilamino enantiomericamente enriquecidos, composicion plaguicida y su uso para prevenir la infeccion parasitaria
MY155497A (en)	2008-11-19	2015-10-30	Merial Inc	Compositions comprising an aryl pyrazole and/or a formamidine, methods and use thereof
JP2012509879A (ja)	2008-11-21	2012-04-26	ハイポイントファーマシューティカルズ，リミティドライアビリティカンパニー	アダマンチルベンズアミド化合物
JP5595412B2 (ja)	2008-12-04	2014-09-24	メリアルリミテッド	二量体アベルメクチン及びミルベマイシン誘導体
CA2965223C (en)	2008-12-22	2019-09-24	Chemocentryx, Inc.	C5ar antagonists
PL2565193T3 (pl)	2009-01-23	2014-07-31	Rigel Pharmaceuticals Inc	Kompozycje i sposoby hamowania szlaku JAK
EP2396305A1 (en)	2009-02-13	2011-12-21	Allergan, Inc.	4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2010093849A2 (en)	2009-02-13	2010-08-19	Amgen Inc.	Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
EP3241553B1 (en)	2009-02-13	2019-04-10	Allergan, Inc.	Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
PE20120056A1 (es)	2009-02-24	2012-02-05	Merck Sharp & Dohme	Derivados de indol como antagonistas del receptor crth2
GB0904044D0 (en)	2009-03-09	2009-04-22	Sosei R & D Ltd	The treatment of inflammatory disorders and pain
EP2406282A1 (en)	2009-03-11	2012-01-18	Novo Nordisk A/S	Interleukin-21 variants having antagonistic binding to the il-21 receptor
US8511216B2 (en) *	2009-03-30	2013-08-20	Kanzaki Kokyukoki Mfg. Co., Ltd.	Hydraulic actuator unit
US20100256385A1 (en) *	2009-04-02	2010-10-07	Allergan, Inc.	Prostaglandin e receptor antagonists
US8343976B2 (en) *	2009-04-20	2013-01-01	Institute For Oneworld Health	Compounds, compositions and methods comprising pyrazole derivatives
EP2427243A4 (en)	2009-05-05	2012-11-21	Vapogenix Inc	NEW FORMULATIONS OF VOLATILE ANESTHETICS AND METHOD OF ADMINISTRATION
WO2010134074A1 (en)	2009-05-19	2010-11-25	Neuroderm Ltd	Compositions for continuous administration of dopa decarboxylase inhibitors
WO2011009061A1 (en)	2009-07-17	2011-01-20	Allergan, Inc.	Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
CN102470135A (zh)	2009-07-28	2012-05-23	里格尔药品股份有限公司	抑制jak途径的组合物和方法
US20110039900A1 (en)	2009-08-11	2011-02-17	Allergan, Inc.	Isothiozoles for treating conditions of the eye
JP2013502587A (ja) *	2009-08-20	2013-01-24	ティダブリューアイ・バイオテクノロジー・インコーポレイテッド	糖尿病の診断および治療効果の決定方法
AU2010289703A1 (en)	2009-08-26	2012-04-12	Allergan, Inc.	Method of treating compulsive disorders with alpha-2B adrenergic receptor agonists
CA2771352A1 (en)	2009-09-02	2011-03-10	Merck Sharp & Dohme Corp.	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2011034951A2 (en)	2009-09-15	2011-03-24	The Regents Of The University Of California	Assisted enzyme replacement therapy
EP2480531B1 (en)	2009-09-21	2014-11-05	ChemoCentryx, Inc.	Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
ES2467923T3 (es)	2009-09-30	2014-06-13	Transtech Pharma, Llc	Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
EP2504311B1 (en)	2009-11-25	2015-08-12	Cytometix, Inc.	Arachidonic acid analogs and methods for analgesic treatment using same
CN102712583B (zh)	2009-12-04	2015-04-08	梅里亚有限公司	农药用双-有机硫化合物
RS54772B1 (sr)	2009-12-17	2016-10-31	Merial Sas	Antiparazitska jedinjenja dihidroazola i kompozicije koje ih sadrže
BR112012014933B1 (pt)	2009-12-17	2020-10-27	Merial, Inc.	composições que compreendem compostos lactonas macrocíclicas e spirodioxepinoindóis
CN103664873B (zh) *	2009-12-30	2016-06-15	深圳信立泰药业股份有限公司	作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
JP2013518097A (ja)	2010-01-26	2013-05-20	イッサムリサーチディヴェロップメントカンパニーオブザヘブリューユニバーシティーオブエルサレムエルティーディー	肺高血圧を予防および治療するための組成物および方法
US9090584B2 (en) *	2010-01-26	2015-07-28	Allergan, Inc.	Therapeutic agents for treatment of ocular hypertension
US8299068B2 (en)	2010-01-29	2012-10-30	Allergan, Inc.	Therapeutically active cyclopentanes
JP6045347B2 (ja)	2010-02-03	2016-12-14	ファーマツービーリミテッド	ラサギリンの持続放出性製剤およびその使用
GB201002530D0 (en)	2010-02-15	2010-03-31	Univ Wolverhampton The	Di-aspirin derivatives
WO2011103018A1 (en)	2010-02-18	2011-08-25	High Point Pharmaceuticals, Llc	Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
ES2550667T3 (es)	2010-02-18	2015-11-11	Vtv Therapeutics Llc	Derivados de fenilheteroarilo y métodos de uso de los mismos
US8853212B2 (en)	2010-02-22	2014-10-07	Merck Sharp & Dohme Corp	Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
JP6155187B2 (ja)	2010-03-30	2017-06-28	ヴァーセオンコーポレイション	トロンビンの阻害剤としての多置換芳香族化合物
UA108641C2 (uk)	2010-04-02	2015-05-25		Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
WO2011130716A2 (en)	2010-04-16	2011-10-20	Access Pharmaceuticals, Inc.	A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
CN103096889A (zh)	2010-04-20	2013-05-08	寰宇一家健康研究所	包含1,3,4-噁二唑衍生物的化合物、组合物和方法
WO2011133600A1 (en)	2010-04-20	2011-10-27	Institute For Oneworld Health	Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
JP2013526514A (ja)	2010-05-10	2013-06-24	ラディカル・セラピューティックス・インコーポレイテッド	リポ酸およびニトロキシド誘導体およびその使用
WO2011146358A1 (en)	2010-05-21	2011-11-24	Merck Sharp & Dohme Corp.	Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
PT2576524T (pt)	2010-05-26	2017-11-17	Vtv Therapeutics Llc	Resumo
ES2664872T3 (es)	2010-06-18	2018-04-23	Taiho Pharmaceutical Co., Ltd	Moduladores PRPK-TPRKB y sus usos
CA2803920A1 (en)	2010-06-24	2011-12-29	Richard Beard	Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
PT2585064T (pt)	2010-06-24	2017-08-08	Chemocentryx Inc	Antagonistas do c5ar
US8492424B2 (en)	2010-07-01	2013-07-23	Allergan, Inc.	Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US8859606B2 (en)	2010-07-01	2014-10-14	Allergan, Inc.	Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US9714238B2 (en)	2010-07-02	2017-07-25	Allergan, Inc.	Therapeutic agents for ocular hypertension
EA024450B1 (ru)	2010-07-02	2016-09-30	Юниверсити Оф Вирджиния Пэтент Фаундейшн	Молекулярно-генетический подход к лечению и диагностике алкогольной и наркотической зависимости
WO2012003145A2 (en)	2010-07-02	2012-01-05	Allergan, Inc.	Therapeutic agents for ocular hypertension
AU2011282742B2 (en)	2010-07-28	2015-08-27	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
WO2012016569A1 (en)	2010-08-05	2012-02-09	Conrig Pharma Aps	Deuterated tandospirone derivatives as 5-ht1a receptor agonists
HUE038366T2 (hu)	2010-08-16	2018-10-29	Allergan Inc	Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához
RU2013111971A (ru)	2010-08-20	2014-09-27	Аллерган, Инк.	Соединения, действующие на множественные рецепторы простагландина, дающие общую противовоспалительную реакцию
WO2012032513A1 (en)	2010-09-07	2012-03-15	Bar-Ilan University	Boranophosphate derivatives for the treatment of osteoarthritis
WO2012032524A1 (en)	2010-09-09	2012-03-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd	Near infrared fluorescent particles and uses thereof
GB201016880D0 (en)	2010-10-07	2010-11-17	Riotech Pharmaceuticals Ltd	Phosphodiesterase inhibitors
RU2611376C2 (ru)	2010-10-15	2017-02-21	Контера Фарма Апс	Фармацевтическая композиция для лечения, профилактики или облегчения двигательных расстройств и ее применение
US20130315934A1 (en)	2010-10-28	2013-11-28	Yale University	Methods and Compositions for Assessing and Treating Cancer
WO2012059932A1 (en)	2010-11-01	2012-05-10	Aurigene Discovery Technologies Limited	2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
TWI487706B (zh)	2010-11-12	2015-06-11	Merck Sharp & Dohme	六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
EP2640358B1 (en)	2010-11-15	2018-01-03	Neuroderm Ltd	Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
US8822528B2 (en)	2010-11-16	2014-09-02	Merial Limited	Monensin derivatives for the treatment and prevention of protozoal infections
EP3081651A1 (en)	2010-11-24	2016-10-19	Yale University	Compositions and methods for diagnosing and treating diseases and disorders associated with d-dt
US20130296331A1 (en)	2010-11-26	2013-11-07	Technion Research And Development Foundation Ltd.	Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
CA2819457A1 (en)	2010-12-03	2012-06-07	Allergan, Inc.	Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
JP6076913B2 (ja)	2010-12-07	2017-02-08	ドレクセルユニバーシティ	癌からの転移を阻害する方法
GB201020860D0 (en)	2010-12-09	2011-01-26	Univ Wolverhampton	Disulfiram formulation and uses thereof
WO2012079172A1 (en)	2010-12-15	2012-06-21	Isotechnika Pharma Inc.	Cyclosporine analogue molecules modified at amino acid 1 and 3
EP2654421B1 (en)	2010-12-22	2016-10-19	Merck Sharp & Dohme Corp.	Fused heterocyclic indane carboxamide as cgrp receptor antagonists
WO2012093383A1 (en)	2011-01-04	2012-07-12	Radikal Therapeutics Inc.	Compositions and methods for treatment of sepsis and related conditions
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
HUE051738T2 (hu)	2011-01-07	2021-03-29	Anji Pharma Us Llc	Kemoszenzoros receptorligandum-alapú terápiák
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR20140026396A (ko)	2011-03-08	2014-03-05	어섹스 팔마큐티칼스 인코포레이티드	생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
MX343517B (es)	2011-03-10	2016-11-07	Rigel Pharmaceuticals Inc	2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide.
US8476221B2 (en)	2011-03-18	2013-07-02	Halimed Pharmaceuticals, Inc.	Methods and compositions for the treatment of metabolic disorders
CN103703000B (zh)	2011-03-23	2015-11-25	安姆根有限公司	Cdk4/6和flt3的稠合三环双重抑制剂
CN103764621B (zh)	2011-04-06	2015-05-27	威斯康星州医药大学股份有限公司(美国)	环氧化二十碳三烯酸类似物、其制备方法及其应用
HK1207853A1 (en)	2011-04-08	2016-02-12	卡尔丹治疗有限公司	Ortho-fluoro substituted compounds for the treatment of metabolic diseases
WO2012140647A2 (en)	2011-04-11	2012-10-18	Yeda Research And Development Co. Ltd	Albumin binding probes and drug conjugates thereof
WO2012142308A1 (en)	2011-04-13	2012-10-18	Activesite Pharmaceuticals, Inc.	Prodrugs of inhibitors of plasma kallikrein
ES2647072T3 (es)	2011-04-18	2017-12-19	Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft	Niclosamida para el tratamiento de la metástasis en el cáncer
CA2835018C (en)	2011-05-04	2020-04-21	Balance Therapeutics, Inc.	Pentylenetetrazole derivatives
JP2014513692A (ja)	2011-05-09	2014-06-05	ユニバーシティオブバージニアパテントファウンデーション	癌を治療するための組成物及び方法
EP2714028A1 (en)	2011-05-27	2014-04-09	Allergan, Inc.	D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders
EP2714040A1 (en)	2011-06-01	2014-04-09	Concit Pharma ApS	Combinations of serotonin receptor agonists for treatment of movement disorders
US20120329873A1 (en)	2011-06-17	2012-12-27	Li yong-xin	D-serine for the treatment of visual system disorders
ES2618813T3 (es)	2011-06-27	2017-06-22	Merial, Inc.	Compuestos y composiciones de éter amido-piridílico y uso contra los parásitos
US20120329832A1 (en)	2011-06-27	2012-12-27	Jean Delaveau	Novel Insect-Repellent Coumarin Derivatives, Syntheses, and Methods of Use
WO2013005216A1 (en)	2011-07-05	2013-01-10	Radikal Therapeutics Inc.	Compositions and methods for treatment of renal ischemia-reperfusion injury
MX336578B (es)	2011-07-25	2016-01-25	Allergan Inc	Derivados de n-(imidazolidin-2-ilideno)-heterociclopenta[b] pirididina como moduladores de receptores de alfa 2 adrenergicos.
US8609658B2 (en)	2011-07-27	2013-12-17	Allergan, Inc.	N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
WO2013019169A1 (en)	2011-08-01	2013-02-07	Institute For Oneworld Health	Phosphate prodrugs
EP2751137A4 (en)	2011-09-09	2015-06-03	Univ Virginia Patent Found	MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG INDEPENDENCE
EP2763540A4 (en)	2011-09-09	2015-04-22	Univ Yale	COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES
WO2013041042A1 (en)	2011-09-22	2013-03-28	Merck Sharp & Dohme Corp.	Pyrazole carboxamides as janus kinase inhibitors
EP2763535B1 (en)	2011-10-03	2017-06-07	Merck Sharp & Dohme Corp.	Azaindoles as janus kinase inhibitors
TWI549679B (zh)	2011-11-03	2016-09-21	台灣微脂體股份有限公司	疏水性喜樹鹼衍生物之醫藥組合物
US10980798B2 (en)	2011-11-03	2021-04-20	Taiwan Liposome Company, Ltd.	Pharmaceutical compositions of hydrophobic camptothecin derivatives
AU2012340351B2 (en)	2011-11-17	2017-06-15	Boehringer Ingelheim Animal Health USA Inc.	Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof
US9713605B2 (en)	2011-11-18	2017-07-25	Simpson Biotech Co., Ltd.	Ameliorative or preventive effect of Antrodia cinnamomea in arthritis, cartilage destruction, or chondrocyte death
EP2782569A1 (en)	2011-11-21	2014-10-01	Allergan, Inc.	Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
DK2785710T3 (en)	2011-12-01	2017-12-04	Chemocentryx Inc	SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR (4) - ANTAGONISTS
MX356163B (es)	2011-12-01	2018-05-16	Chemocentryx Inc	Anilinas sustituidas como antagonistas de ccr(4).
BR112014013371B1 (pt)	2011-12-02	2020-04-07	Merial Ltd	formulações de moxidectina injetável de ação prolongada e novas formas de cristal de moxidectina
EP2788000B1 (en)	2011-12-06	2018-05-30	Merck Sharp & Dohme Corp.	Pyrrolopyrimidines as janus kinase inhibitors
EP3424904B1 (en)	2011-12-21	2020-12-02	Allergan, Inc.	Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
AU2012358983B2 (en)	2011-12-21	2017-09-14	Allergan, Inc.	Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
US9035071B2 (en)	2011-12-27	2015-05-19	Allergan, Inc.	Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
CA2862266C (en)	2011-12-27	2016-10-04	Allergan, Inc.	Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
KR20200137035A (ko)	2012-01-06	2020-12-08	앤지 파마 유에스 엘엘씨	바이구아나이드 조성물 및 대사 장애를 치료하는 방법
EA033067B1 (ru)	2012-01-06	2019-08-30	Элселикс Терапьютикс, Инк.	Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
WO2013122920A1 (en)	2012-02-17	2013-08-22	Merck Sharp & Dohme Corp.	Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2013130811A1 (en)	2012-02-29	2013-09-06	Chemocentryx, Inc.	Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists
CA2865504A1 (en)	2012-03-23	2013-09-26	Oxigene, Inc.	Compositions and methods for inhibition of cathepsins
WO2013151982A1 (en)	2012-04-03	2013-10-10	Arena Pharmaceuticals, Inc.	Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2013155600A1 (en)	2012-04-16	2013-10-24	Kaneq Pharma	Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
WO2013156861A2 (en)	2012-04-17	2013-10-24	University College Dublin, National University Of Ireland, Dublin	Methods and compounds for treating proliferative disorders and viral infections
US9388127B2 (en)	2012-04-17	2016-07-12	University College Dublin, National University Of Ireland, Dublin	Thromboxane receptor antagonists
NZ700474A (en)	2012-04-18	2016-10-28	Contera Pharma Aps	Orally available pharmaceutical formulation suitable for improved management of movement disorders
EP2846798B1 (en)	2012-05-09	2018-04-04	Merck Sharp & Dohme Corp.	Aliphatic spirolactam cgrp receptor antagonists
WO2013169567A1 (en)	2012-05-09	2013-11-14	Merck Sharp & Dohme Corp.	Spirolactam cgrp receptor antagonists
US9227973B2 (en)	2012-05-09	2016-01-05	Merck Sharp & Dohme Corp.	Pyridine CGRP receptor antagonists
US20130310340A1 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
WO2013190497A2 (en)	2012-06-21	2013-12-27	Radikal Therapeutics Inc.	Compositions and methods for treatment of inflammatory diseases of the lung
US20140024621A1 (en)	2012-07-23	2014-01-23	Ms Therapeutics Limited	Aminopyridine compounds and their uses
EP2874622A4 (en)	2012-07-23	2015-12-30	Merck Sharp & Dohme	TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
EP3378472A1 (en)	2012-08-09	2018-09-26	Dynamis Therapeutics, Inc.	Combinations of meglumine
WO2014036022A1 (en)	2012-08-29	2014-03-06	Amgen Inc.	Quinazolinone compounds and derivatives thereof
EP2895172B1 (en)	2012-09-12	2019-02-06	Rigel Pharmaceuticals, Inc.	Treatment for vitiligo
US9217023B2 (en)	2012-10-19	2015-12-22	Txp Pharma Gmbh	Alpha- and gamma-MSH analogues
JP6322200B2 (ja)	2012-11-16	2018-05-09	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	ヒトホスファチジルイノシトール３−キナーゼデルタのプリン阻害剤
NZ723198A (en)	2012-11-20	2018-11-30	Boehringer Ingelheim Animal Health Usa Inc	Anthelmintic compounds and compositions and methods of using thereof
AU2013355054B2 (en)	2012-12-07	2017-08-24	Chemocentryx, Inc.	Diazole lactams
US9169248B2 (en)	2012-12-21	2015-10-27	Chemocentryx, Inc.	Diazole amides
CA2898720A1 (en)	2013-01-21	2014-07-24	Allergan, Inc.	Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
CA2899281C (en)	2013-01-25	2022-05-31	Rigel Pharmaceuticals, Inc.	Pyrimidinediamine compounds for use in treating or preventing autoimmune alopecia
WO2014134774A1 (en)	2013-03-04	2014-09-12	Merck Sharp & Dohme Corp.	Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014136059A2 (en)	2013-03-05	2014-09-12	Radikal Therapeutics Inc.	Prodrugs of multifunctional nitroxide derivatives and uses thereof
PT2968218T (pt)	2013-03-13	2021-09-24	Neuroderm Ltd	Combinação para tratamento da doença de parkinson
BR112015022854A2 (pt)	2013-03-14	2017-07-18	Alkermes Pharma Ireland Ltd	pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças
HK1214252A1 (zh)	2013-03-15	2016-07-22	Verseon Corporation	作為凝血酶抑制劑的鹵代吡唑
CN110179795A (zh)	2013-03-15	2019-08-30	维颂公司	作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
US9051294B2 (en)	2013-04-30	2015-06-09	Allergan, Inc.	Therapeutic agents
WO2014194209A1 (en)	2013-05-31	2014-12-04	Allergan, Inc.	Substituted cyclopentenes as therapeutic agents
RU2673737C2 (ru)	2013-07-02	2018-11-29	ЭКОПЛЭНЕТ ЭНВАЙРОНМЕНТАЛ, ЭлЭлСи	Композиции летучих органических веществ, обладающие антимикробной активностью
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
WO2015026683A1 (en)	2013-08-22	2015-02-26	Merck Sharp & Dohme Corp.	Compounds inhibiting leucine-rich repeat kinase enzyme activity
TWI622406B (zh)	2013-10-23	2018-05-01	善笙生物科技股份有限公司	來自牛樟芝菌絲體的化合物及混合物的用途
US9315486B2 (en)	2013-10-29	2016-04-19	Allergan, Inc.	Therapeutic cyclopentanols, compositions thereof, and methods for use thereof
WO2015066277A1 (en)	2013-11-01	2015-05-07	Merial Limited	Antiparisitic and pesticidal isoxazoline compounds
EP3068389B1 (en)	2013-11-14	2019-10-02	Merck Sharp & Dohme Corp.	Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3076968B1 (en)	2013-12-02	2019-04-17	ChemoCentryx, Inc.	Ccr6 compounds
WO2015094864A1 (en)	2013-12-20	2015-06-25	Allergan, Inc.	Secondary amines as therapeutic agents
US9365569B2 (en)	2014-01-27	2016-06-14	Allergan, Inc.	Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
JP6491669B2 (ja)	2014-02-05	2019-03-27	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｃｇｒｐ活性化合物の錠剤製剤
US12168004B2 (en)	2014-02-05	2024-12-17	Merck Sharp & Dohme Llc	Treatment of migraine
ES2967693T3 (es)	2014-03-13	2024-05-03	Neuroderm Ltd	Composiciones del inhibidor de la dopa descarboxilasa
US10258585B2 (en)	2014-03-13	2019-04-16	Neuroderm, Ltd.	DOPA decarboxylase inhibitor compositions
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
WO2015162483A1 (en)	2014-04-22	2015-10-29	Txp Pharma Gmbh	Alpha- and gamma-msh analogues
EP3838285A1 (en)	2014-04-22	2021-06-23	TXP Pharma GmbH	Peptide analogues with branched amino acid probe(s)
WO2015162486A1 (en)	2014-04-22	2015-10-29	Txp Pharma Gmbh	Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
US9394273B2 (en)	2014-05-15	2016-07-19	Allergan, Inc.	Therapeutic prostaglandin receptor agonists
ES2842592T3 (es)	2014-05-19	2021-07-14	Boehringer Ingelheim Animal Health Usa Inc	Compuestos antihelmínticos
WO2015179815A1 (en)	2014-05-22	2015-11-26	Allergan, Inc.	Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
KR101636758B1 (ko) *	2014-05-30	2016-07-06	디씨에스이엔지 주식회사	회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치
EP3152188B1 (en)	2014-06-06	2019-02-13	Allergan, Inc.	Novel ep4 agonists as therapeutic compounds
US9908923B2 (en)	2014-06-11	2018-03-06	The Medical College Of Wisconsin, Inc.	Monomeric CXCL121 peptide and methods of use thereof
WO2016009341A1 (en)	2014-07-14	2016-01-21	Radikal Therapeutics Inc.	Thioredoxin mimetic prodrugs and uses thereof
GB201417828D0 (en)	2014-10-08	2014-11-19	Cereno Scient Ab	New methods and compositions
WO2016036586A1 (en)	2014-09-03	2016-03-10	Merck Sharp & Dohme Corp.	Compounds inhibiting leucine-rich repeat kinase enzyme activity
US10189810B2 (en)	2014-09-17	2019-01-29	Verseon Corporation	Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
MX2017004344A (es)	2014-10-06	2017-06-07	Chemocentryx Inc	COMPOSICIONES Y METODOS PARA TRATAR ENFERMEDAD INFLAMATORIA DE INTESTINO USANDO UNA TERAPIA DE COMBINACION DE INHIBIDORES DE MOLECULA PEQUENA DEL RECEPTOR DE QUIMIOCINA C-C TIPO 9 (CCR9) Y ANTICUERPOS BLOQUEADORES ANTI-A4ß7 INTEGRINA.
WO2016086261A1 (en)	2014-12-02	2016-06-09	Prana Biotechnology Limited	4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
DK3230255T3 (da)	2014-12-09	2020-06-22	Ezekiel Golan	Regulatorer af uhæmmet adfærd
US9899696B2 (en) *	2015-01-21	2018-02-20	Lockheed Martin Advanced Energy Storage, Llc	Solid buffer materials for electrolyte solutions and flow batteries utilizing same
MA41558B1 (fr)	2015-02-20	2023-02-28	Univ Leland Stanford Junior	Compositions d'allergènes mélangés et leurs procédés d'utilisation
CN107405333A (zh)	2015-02-27	2017-11-28	维颂公司	作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
EA201791982A1 (ru)	2015-03-09	2020-02-17	Интекрин Терапьютикс, Инк.	Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
KR20250078598A (ko)	2015-05-19	2025-06-02	예일 유니버시티	병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
LT3298027T (lt)	2015-05-20	2021-08-10	Boehringer Ingelheim Animal Health USA Inc.	Antihelmintiniai depsipeptido junginiai
DK3300500T3 (da)	2015-05-20	2020-05-18	Amgen Inc	Triazolagonister af apj-receptoren
US11571462B2 (en)	2015-06-03	2023-02-07	The Medical College Of Wisconsin, Inc.	Engineered CCL20 locked dimer polypeptide
AU2016271292B2 (en)	2015-06-03	2022-04-14	The Medical College Of Wisconsin, Inc.	An engineered CCL20 locked dimer polypeptide
KR20240025721A (ko)	2015-06-15	2024-02-27	더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티	노화와 연관된 질환을 치료하기 위한 방법 및 조성물
AU2016278040B2 (en)	2015-06-16	2019-07-04	Nanophagix LLC	Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
ES2858551T3 (es)	2015-06-16	2021-09-30	Atxa Therapeutics Ltd	Antagonistas del receptor de tromboxano
WO2016205754A1 (en)	2015-06-19	2016-12-22	University Of Southern California	Compositions and methods for modified nutrient delivery
US10744070B2 (en)	2015-06-19	2020-08-18	University Of Southern California	Enteral fast access tract platform system
WO2017003822A1 (en)	2015-06-30	2017-01-05	Galleon Pharmaceuticals, Inc.	Novel breathing control modulating compounds, and methods of making and using same
US11173197B2 (en)	2015-07-07	2021-11-16	Bluewillow Biologics, Inc.	Methods and compositions for nanoemulsion vaccine formulations
EP3334706B1 (en)	2015-08-10	2020-09-30	Ramot at Tel-Aviv University Ltd.	Pillararenes and uses thereof
US11497813B2 (en)	2015-11-02	2022-11-15	Biovinc, Llc	Bortezomib conjugates and methods using same
WO2017077528A2 (en)	2015-11-02	2017-05-11	Salzman Lovelace Investments, Ltd.	Methods and pharmaceutical compositions for treatment of lung inflammation
US10660884B2 (en)	2015-11-02	2020-05-26	University Of Rochester	Phosphonate-chloroquine conjugates and methods using same
TWI734715B (zh)	2015-11-19	2021-08-01	美商卡默森屈有限公司	趨化因子受體調節劑
TWI724056B (zh)	2015-11-19	2021-04-11	美商卡默森屈有限公司	Ｃｘｃｒ２抑制劑
WO2017087936A1 (en)	2015-11-20	2017-05-26	Yale University	Compositions for treating ectopic calcification disorders, and methods using same
CN108601790B (zh)	2016-01-14	2026-01-27	凯莫森特里克斯股份有限公司	C3肾小球病的治疗方法
RU2743747C2 (ru)	2016-01-20	2021-02-25	Кемосентрикс, Инк.	2-оксиндольные соединения
JP7003045B2 (ja)	2016-02-11	2022-02-04	シェヴィオンモデハイ	神経変性の治療のための方法及び医薬組成物
UY37137A (es)	2016-02-24	2017-09-29	Merial Inc	Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2017153977A1 (en)	2016-03-08	2017-09-14	Salzman Lovelace Investments, Ltd.	Solid formulations of resolvins and uses thereof
AU2017246228B2 (en)	2016-04-04	2021-04-15	Chemocentryx, Inc.	Soluble C5aR antagonists
US10946020B2 (en)	2016-04-06	2021-03-16	University Of Virginia Patent Foundation	Compositions and methods for treating cancer
WO2017192485A1 (en)	2016-05-03	2017-11-09	Amgen Inc.	Heterocyclic triazole compounds as agonists of the apj receptor
WO2017201390A1 (en)	2016-05-19	2017-11-23	The Regents Of The University Of Michigan	Novel adjuvant compositions
EP4094778B1 (en)	2016-06-03	2024-05-15	Novacyte Therapeutics Company.,LTD	Polymer linkers and their uses
US10036024B2 (en)	2016-06-03	2018-07-31	Purdue Research Foundation	siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
WO2018005374A1 (en)	2016-06-27	2018-01-04	Chemocentryx, Inc.	Immunomodulator compounds
AU2017297718B2 (en)	2016-07-11	2023-06-08	Contera Pharma A/S	Pulsatile drug delivery system for treating morning akinesia
US20210330599A1 (en)	2016-08-01	2021-10-28	University Of Rochester	Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
WO2018039508A1 (en)	2016-08-25	2018-03-01	Merial, Inc.	Method for reducing unwanted effects in parasiticidal treatments
US10449230B2 (en)	2016-10-06	2019-10-22	The Regents Of The University Of California	Polymyxin derived cell penetrating scaffolds
WO2018071535A1 (en)	2016-10-14	2018-04-19	Merial, Inc.	Pesticidal and parasiticidal vinyl isoxazoline compounds
EP3529254B1 (en)	2016-11-03	2023-02-22	Laurence I. Wu	Prodrugs of clofarabine
TWI794190B (zh)	2016-11-07	2023-03-01	加拿大商愛彼特生物製藥公司	含有取代的吡啶酮之三環化合物及其使用方法
EP3541803B1 (en)	2016-11-16	2020-12-23	Amgen Inc.	Triazole pyridyl compounds as agonists of the apj receptor
US11046680B1 (en)	2016-11-16	2021-06-29	Amgen Inc.	Heteroaryl-substituted triazoles as APJ receptor agonists
US11020395B2 (en)	2016-11-16	2021-06-01	Amgen Inc.	Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
WO2018093576A1 (en)	2016-11-16	2018-05-24	Amgen Inc.	Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541792B1 (en)	2016-11-16	2020-12-23	Amgen Inc.	Triazole furan compounds as agonists of the apj receptor
CA3044038A1 (en)	2016-11-16	2018-05-24	Boehringer Ingelheim Animal Health USA Inc.	Anthelmintic depsipeptide compounds
WO2018093579A1 (en)	2016-11-16	2018-05-24	Amgen Inc.	Triazole phenyl compounds as agonists of the apj receptor
MX2021014356A (es)	2016-11-23	2022-11-24	Chemocentryx Inc	Metodo para tratar glomeruloesclerosis segmentaria focal.
WO2018106928A1 (en)	2016-12-08	2018-06-14	Contravir Pharmaceuticals, Inc.	Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
AU2017376398B2 (en)	2016-12-14	2021-07-15	Intervet International B.V.	Aminopyrazoles as selective janus kinase inhibitors
AU2018238138A1 (en)	2017-03-21	2019-10-17	Arbutus Biopharma Corporation	Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
AU2018249822A1 (en)	2017-04-03	2019-10-31	Coherus Biosciences Inc.	PPArgamma agonist for treatment of progressive supranuclear palsy
TW201902507A (zh)	2017-04-14	2019-01-16	美商康特維爾製藥公司	治療病毒感染之組合療法
DE202017002464U1 (de)	2017-05-09	2017-06-12	St. Lotus Biotech Corp.	Pflanzliche Zusammensetzung zur Vorbeugung oder Linderung von ischämischem Schlaganfall
US11484543B2 (en)	2017-05-18	2022-11-01	The Rockefeller University	Compositions and methods for diagnosing and treating diseases and disorders associated with mutant KCNJ5
EP4092013A1 (en)	2017-06-20	2022-11-23	Imbria Pharmaceuticals, Inc.	Compositions and methods for increasing efficiency of cardiac metabolism
CN111225665B (zh)	2017-08-08	2023-12-08	凯莫森特里克斯股份有限公司	大环免疫调节剂
BR112020003217A2 (pt)	2017-08-14	2020-10-06	Boehringer Ingelheim Animal Health USA Inc.	compostos pesticidas e parasiticidas de pirazolisoxazolina
CN111194307A (zh)	2017-08-23	2020-05-22	嘉维什-嘉利理生物应用有限公司	用于治疗动脉粥样硬化性心血管疾病的组合物和方法
CN118267479A (zh)	2017-09-25	2024-07-02	凯莫森特里克斯股份有限公司	使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗
AU2018347361A1 (en)	2017-10-11	2020-04-30	Chemocentryx, Inc.	Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
AU2018359237A1 (en)	2017-10-31	2020-04-30	Chemocentryx, Inc.	C5aR inhibitor reduction of urinary sCD163
US11149040B2 (en)	2017-11-03	2021-10-19	Amgen Inc.	Fused triazole agonists of the APJ receptor
US20200323895A1 (en)	2017-11-27	2020-10-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic	Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
ES2980175T3 (es)	2017-12-22	2024-09-30	Chemocentryx Inc	Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR
MX2020006460A (es)	2017-12-22	2020-11-06	Chemocentryx Inc	Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
IL275839B2 (en)	2018-01-08	2024-02-01	Chemocentryx Inc	Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist
WO2019141957A1 (en)	2018-01-19	2019-07-25	Cado Biotechnology Ivs	N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
US20200352906A1 (en)	2018-02-05	2020-11-12	Shenzhen Ionova Life Science Co., Ltd.	Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases
EP3749096A1 (en)	2018-02-08	2020-12-16	Boehringer Ingelheim Animal Health USA Inc.	Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
CN112313221A (zh)	2018-02-13	2021-02-02	比托邦制药有限公司	大麻素衍生物和缀合物以及其用途
JP7387616B2 (ja)	2018-02-22	2023-11-28	ケモセントリックス，インコーポレイティド	Ｐｄ－ｌ１アンタゴニストとしてのインダン－アミン
EP3759225A1 (en)	2018-03-02	2021-01-06	Sixfold Bioscience Ltd.	Compositions for delivery of cargo to cells
EP3773579A4 (en)	2018-03-26	2022-03-09	Clear Creek Bio, Inc.	COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
WO2019190822A1 (en)	2018-03-28	2019-10-03	Vtv Therapeutics Llc	Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en)	2018-03-28	2019-10-03	Vtv Therapeutics Llc	Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019195159A1 (en)	2018-04-02	2019-10-10	Chemocentryx, Inc.	PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
EP3552605A1 (en)	2018-04-11	2019-10-16	Univerzita Palackého V Olomouchi	Mcoppb for use as medicament
WO2019213006A1 (en)	2018-05-01	2019-11-07	Amgen Inc.	Substituted pyrimidinones as agonists of the apj receptor
AU2019279761A1 (en)	2018-05-29	2020-12-10	Cersci Therapeutics, Inc.	Compounds for pain treatment, compositions comprising same, and methods of using same
US12383545B1 (en)	2018-06-08	2025-08-12	Allergan Pharmaceuticals International Limited	Treatment of migraine
WO2019236984A1 (en)	2018-06-08	2019-12-12	The Medical College Of Wisconsin, Inc.	Methods of treating vascular leakage using cxcl12 peptides
AU2019301510B2 (en)	2018-07-09	2024-06-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Anthelminthic heterocyclic compounds
TWI869058B (zh)	2018-07-27	2025-01-01	加拿大商愛彼特生物製藥公司	經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
AU2019334202A1 (en)	2018-09-06	2021-03-25	Innopharmascreen, Inc.	Methods and compositions for treatment of asthma or parkinson's disease
JP7464591B2 (ja)	2018-10-10	2024-04-09	ブイティーブイ・セラピューティクス・エルエルシー	［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
WO2020081361A1 (en)	2018-10-17	2020-04-23	Imbria Pharmaceuticals, Inc.	Methods of treating rheumatic diseases using trimetazidine-based compounds
WO2020092136A1 (en)	2018-10-31	2020-05-07	Merck Sharp & Dohme Corp.	N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US20220000880A1 (en)	2018-11-01	2022-01-06	Rigel Pharmaceuticals, Inc.	Method and composition embodiments for treating acute myeloid leukemia
CN113260419A (zh)	2018-11-20	2021-08-13	勃林格殷格翰动物保健美国公司	吲唑基氰基乙基氨基化合物、其组合物、其制备方法和其使用方法
TW202415643A (zh)	2018-12-12	2024-04-16	加拿大商愛彼特生物製藥公司	經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
US20200246317A1 (en)	2019-02-01	2020-08-06	Cersci Therapeutics, Inc.	Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020159565A1 (en)	2019-02-01	2020-08-06	Cersci Therapeutics, Inc.	Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
CA3133100A1 (en)	2019-03-19	2020-09-24	Boehringer Ingelheim Animal Health USA Inc.	Anthelmintic aza-benzothiophene and aza-benzofuran compounds
IL287617B2 (en)	2019-05-09	2024-11-01	Feinstein Institutes For Medical Research	Hmgb1 antagonist
US20200377518A1 (en)	2019-05-29	2020-12-03	Rigel Pharmaceuticals, Inc.	Method of preventing and treating thrombosis
WO2020243120A1 (en)	2019-05-31	2020-12-03	Imbria Pharmaceuticals, Inc.	Methods of treating fibrosis using compounds that promote glucose oxidation
US12319671B2 (en)	2019-06-06	2025-06-03	Merck Sharp & Dohme Llc	1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
JP7693644B2 (ja)	2019-07-08	2025-06-17	リゾルート，インコーポレイティド	血漿カリクレイン阻害薬の調製プロセス
BR112021025888A2 (pt)	2019-07-10	2022-04-26	Chemocentryx Inc	Indanos como inibidores de pd-l1
BR112022001418A2 (pt)	2019-08-08	2022-06-07	Rigel Pharmaceuticals Inc	Compostos e método para tratar a síndrome de liberação de citocinas
ES2970382T3 (es)	2019-08-14	2024-05-28	Rigel Pharmaceuticals Inc	Método para bloquear o mejorar el síndrome de liberación de citocinas
AU2020368393B2 (en)	2019-10-16	2026-01-08	Chemocentryx, Inc.	Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CN114555080B (zh)	2019-10-16	2025-10-10	凯莫森特里克斯股份有限公司	用于治疗pd-l1疾病的杂芳基联苯胺
EP4048261A4 (en)	2019-10-25	2023-11-22	Merck Sharp & Dohme LLC	N-(HETEROARYL)-QUINAZOLINE-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
CA3235574A1 (en)	2019-11-08	2021-05-14	Chemocentryx, Inc.	Salt forms of a complement component c5a receptor
US10792360B1 (en)	2019-11-21	2020-10-06	Chemocentryx, Inc.	Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
WO2021123394A1 (en)	2019-12-20	2021-06-24	University Of Copenhagen	G protein-coupled receptor modulators and a pharmaceutical composition
US20210300873A1 (en)	2020-03-20	2021-09-30	Clear Creek Bio, Inc.	Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
BR112022019349A2 (pt)	2020-03-27	2022-11-16	Aclaris Therapeutics Inc	Forma cristalina, composição farmacêutica, comprimido e método para isolar um composto
TWI904146B (zh)	2020-03-31	2025-11-11	美商卡默森屈有限公司	使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法
JP7821119B2 (ja)	2020-04-23	2026-02-26	エーゼットセラピーズ，インコーポレイテッド	Ｈｌａクラスｉｍｈｃの細胞切除
AU2021260118A1 (en)	2020-04-24	2022-11-17	Nuvamid Sa	Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
EP3901160A1 (en)	2020-04-25	2021-10-27	Nuvamid SA	Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
WO2021220053A2 (en)	2020-04-27	2021-11-04	Sixfold Bioscience Ltd.	Compositions containing nucleic acid nanoparticles with modular functionality
CN115461047A (zh)	2020-04-30	2022-12-09	安妮特·M·托维亚	用于治疗细胞因子风暴的组合物和方法
US20230210899A1 (en)	2020-05-28	2023-07-06	Aztherapies, Inc.	CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
KR20230028268A (ko)	2020-05-29	2023-02-28	뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드	구충성 헤테로시클릭 화합물
US11780811B2 (en)	2020-06-30	2023-10-10	Imbria Pharmaceuticals, Inc.	Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en)	2020-06-30	2022-12-20	Imbria Pharmaceuticals, Inc.	Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
EP4178547A1 (en)	2020-07-07	2023-05-17	ATXA Therapeutics Limited	Thromboxane receptor antagonist formulations
US20230287031A1 (en)	2020-07-17	2023-09-14	Université De Bretagne Occidentale	New glycolipids and use thereof as sk3 ion channel modulators
CN116390712A (zh)	2020-07-29	2023-07-04	阿勒根制药国际有限公司	治疗偏头痛
WO2022029275A1 (en)	2020-08-06	2022-02-10	Nuvamid Sa	Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
JP7842734B2 (ja)	2020-08-07	2026-04-08	ヌバミッドエスエー	抗悪性腫瘍薬誘発毒性の処置および防止におけるニコチンアミドモノヌクレオチド誘導体およびその使用
WO2022034062A1 (en)	2020-08-12	2022-02-17	Txp Pharma Ag	Exendin-4 peptide analogues
EP4213832A4 (en)	2020-09-18	2024-10-16	Merck Sharp & Dohme LLC	Modified benzofuran-carboxamides as glucosylceramide synthase inhibitors
EP4216949A4 (en)	2020-09-28	2024-12-11	Yale University	Selective agonists of 5-ht2a receptor and methods of use
KR20230090336A (ko)	2020-10-13	2023-06-21	베타바이브 리미티드	당뇨병 및 관련된 대사성 질환을 치료하기 위한 방법 및 화합물
EP4236950A4 (en)	2020-10-29	2024-10-23	Merck Sharp & Dohme LLC	N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
GB202017255D0 (en)	2020-10-30	2020-12-16	Queens Univ Of Belfast	Immunomodulatory agent
GB202017251D0 (en)	2020-10-30	2020-12-16	Queens Univ Of Belfast	Neurodegenerative treatment
US11213502B1 (en)	2020-11-17	2022-01-04	Neuroderm, Ltd.	Method for treatment of parkinson's disease
US11844754B2 (en)	2020-11-17	2023-12-19	Neuroderm, Ltd.	Methods for treatment of Parkinson's disease
US11331293B1 (en)	2020-11-17	2022-05-17	Neuroderm, Ltd.	Method for treatment of Parkinson's disease
CA3200651A1 (en)	2020-12-04	2022-06-09	Joel Ernest George HARDY	Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool
US11730733B2 (en)	2020-12-10	2023-08-22	Imbria Pharmaceuticals, Inc.	Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
US11793807B2 (en)	2020-12-10	2023-10-24	Imbria Pharmaceuticals, Inc.	Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
US12076318B2 (en)	2020-12-10	2024-09-03	Imbria Pharmaceuticals, Inc.	Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
US11969422B2 (en)	2020-12-10	2024-04-30	Imbria Pharmaceuticals, Inc.	Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
WO2022129490A1 (en)	2020-12-18	2022-06-23	Nuvamid Sa	Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder
CA3206184A1 (en)	2020-12-22	2022-06-30	Allergan Pharmaceuticals International Limited	Treatment of migraine
EP4288041A1 (en)	2021-02-08	2023-12-13	Bausch Health Ireland Limited	Amiselimod for preventing, treating, or ameliorating ulcerative colitis
WO2022184685A1 (en)	2021-03-01	2022-09-09	Nuvamid Sa	Nicotinamide mononucleotide derivatives and use thereof for the treatment and/or prevention of long covid-19
EP4070799A1 (en)	2021-04-08	2022-10-12	Nuvamid SA	Compositions for the improvement of sport performance
EP4079310A1 (en)	2021-04-20	2022-10-26	Nuvamid SA	Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
EP4079311B1 (en)	2021-04-20	2025-10-01	Nuvamid SA	Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
US11883396B2 (en)	2021-05-03	2024-01-30	Imbria Pharmaceuticals, Inc.	Methods of treating kidney conditions using modified forms of trimetazidine
US20240285702A1 (en)	2021-05-31	2024-08-29	Cannabotech Ltd.	Compositions comprising a cannabinoid and uses thereof
EP4355335A1 (en)	2021-06-17	2024-04-24	Nuvamid SA	Nicotinamide mononucleotide derivatives and use thereof for the treatment of heart failure with preserved ejection fraction
US20250066335A1 (en)	2021-06-18	2025-02-27	University Of Copenhagen	Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
EP4380577A1 (en)	2021-08-02	2024-06-12	Nuvamid SA	Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
US12018016B2 (en)	2021-08-18	2024-06-25	Amgen Inc.	Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors
WO2023049920A1 (en)	2021-09-27	2023-03-30	Allergan Pharmaceuticals International Limited	Combination comprising atogepant for treating migraine
US12447198B2 (en)	2021-10-12	2025-10-21	Betavive Ltd.	Peptides and fragments for treating diabetes and associated metabolic diseases
JP2025511436A (ja)	2022-09-02	2025-04-16	メルク・シャープ・アンド・ドーム・エルエルシー	エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
US20260083759A1 (en)	2022-09-06	2026-03-26	Hadasit Medical Research Services And Development Ltd	Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders
CN120417935A (zh)	2022-10-25	2025-08-01	默沙东有限责任公司	依喜替康衍生的adc接头-载荷及其药物组合物和用途
US20240207425A1 (en)	2022-12-14	2024-06-27	Merck Sharp & Dohme Llc	Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
WO2024153775A1 (en)	2023-01-20	2024-07-25	Epics Therapeutics	Piperidine derivatives as mettl3 inhibitors
WO2024194175A1 (en)	2023-03-17	2024-09-26	Atmosr	Adenine derivatives as hsp90 inhibitors
US12161612B2 (en)	2023-04-14	2024-12-10	Neuroderm, Ltd.	Methods and compositions for reducing symptoms of Parkinson's disease
WO2025011733A1 (en)	2023-07-07	2025-01-16	Nuvamid Sa	Nicotinamide mononucleotide and derivatives thereof and use thereof in the treatment and prevention of polycythemia
CN121729233A (zh)	2023-08-14	2026-03-24	纽瑞姆制药（1991）有限公司	Gal475组合物及其使用方法
WO2025064408A1 (en)	2023-09-18	2025-03-27	The Broad Institute, Inc.	Compositions and methods for treating cardiovascular disease
WO2025099725A1 (en)	2023-11-09	2025-05-15	Hadasit Medical Research Services And Development Ltd.	Conjugates and uses thereof
GB2636364A (en)	2023-12-07	2025-06-18	Aramune Tech Limited	Arabinogalactan
WO2025134072A1 (en)	2023-12-21	2025-06-26	Bausch Health Ireland Limited	Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
WO2025176994A1 (en)	2024-02-20	2025-08-28	Analytical Services For Art & Archaeology (Scotland) Ltd	Composition and method of use
WO2025219976A1 (en)	2024-04-19	2025-10-23	Betavive Ltd.	Peptides and fragments for treating diabetes and associated metabolic diseases
GB202405650D0 (en)	2024-04-22	2024-06-05	Royal College Surgeons Ireland	Hdac6 protacs
US12599544B2 (en)	2024-05-09	2026-04-14	Alsteni Medical, Inc.	Intraoral gastrointestinal access device and related methods
WO2026017846A1 (en)	2024-07-19	2026-01-22	Epics Therapeutics	Piperidine derivatives as mettl3 inhibitors for the treatment of carcinomas
WO2026027787A1 (en)	2024-08-02	2026-02-05	The University Court Of The University Of Edinburgh	Cyclophilin modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2211485A (en) *		1940-08-13		Effervescent acetyl salicylic acid
US536155A (en) *		1895-03-19		Pill or tablet
US2312381A (en) *	1940-10-24	1943-03-02	Frank J Bickenheuser	Medicinal tablet
US3062715A (en) *	1953-11-18	1962-11-06	George S Pfaus	Vaginal tablet
GB917456A (en) *	1958-10-30	1963-02-06	Casco Lab Inc	Suppository composition and preparation thereof
US3131123A (en) *	1959-03-13	1964-04-28	Lab Francais De Therapeutique	Enteric tablets and manufacture thereof
US3136692A (en) *	1961-06-30	1964-06-09	Strong Cobb Arner Inc	Effervescent composition containing polyvinylpyrrolidone
GB1093286A (en) *	1965-02-15	1967-11-29	Biorex Laboratories Ltd	Improvements in or relating to dosage unit forms for the administration of medicaments and diagnostic agents
FR5391M (2) *	1965-11-04	1967-10-23
GB1123316A (en) *	1966-12-09	1968-08-14	Wynlit Pharmaceuticals Trust R	Improvements in suppositories
US3495001A (en) *	1968-05-27	1970-02-10	Miles Lab	Effervescent compositions of acetylsalicylic acid
US3887700A (en) *	1969-11-28	1975-06-03	Aspro Nicholas Ltd	Analgesic formulations
US3676549A (en) *	1970-09-30	1972-07-11	Alza Corp	Administration of alkali metal salts of salicylamide
US3764668A (en) *	1970-09-30	1973-10-09	Interx Research Corp	Compositions of salts of salicylamide
GB1359614A (en) *	1971-04-06	1974-07-10	Dev Et De Rech Soc Fr De	Method for the manufacture of effervescent tablets
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en) *	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) *	1974-11-18	1977-07-06	Alza Corp	Process for forming outlet passageways in pills using a laser
US4036228A (en) *	1975-09-11	1977-07-19	Alza Corporation	Osmotic dispenser with gas generating means
US4008719A (en) *	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) *	1976-11-22	1978-09-05	Alza Corporation	Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4160452A (en) *	1977-04-07	1979-07-10	Alza Corporation	Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina

1980
- 1980-04-25 US US06/143,644 patent/US4265874A/en not_active Expired - Lifetime
1981
- 1981-02-12 EP EP81300572A patent/EP0040899B1/en not_active Expired
- 1981-02-12 DE DE8181300572T patent/DE3165901D1/de not_active Expired
- 1981-02-12 AT AT81300572T patent/ATE9267T1/de not_active IP Right Cessation
- 1981-03-19 NZ NZ196561A patent/NZ196561A/xx unknown
- 1981-04-02 PT PT72796A patent/PT72796B/pt not_active IP Right Cessation
- 1981-04-03 IE IE765/81A patent/IE51216B1/en not_active IP Right Cessation
- 1981-04-10 GR GR64674A patent/GR73519B/el unknown
- 1981-04-22 ES ES1981267593U patent/ES267593Y/es not_active Expired
- 1981-04-24 JP JP6154181A patent/JPS56167617A/ja active Granted
- 1981-04-24 DK DK184681A patent/DK152482C/da active
1982
- 1982-03-25 ES ES510822A patent/ES510822A0/es active Granted

Also Published As

Publication number	Publication date
DK184681A (da)	1981-10-26
ES8307092A1 (es)	1983-06-16
IE810765L (en)	1981-10-25
EP0040899A3 (en)	1982-08-11
PT72796A (fr)	1981-05-01
US4265874A (en)	1981-05-05
DE3165901D1 (en)	1984-10-18
ATE9267T1 (de)	1984-09-15
DK152482B (da)	1988-03-07
EP0040899B1 (en)	1984-09-12
ES267593Y (es)	1983-11-16
IE51216B1 (en)	1986-11-12
GR73519B (2)	1984-03-09
ES510822A0 (es)	1983-06-16
JPH044293B2 (2)	1992-01-27
DK152482C (da)	1988-08-01
EP0040899A2 (en)	1981-12-02
JPS56167617A (en)	1981-12-23
ES267593U (es)	1983-05-16
NZ196561A (en)	1983-05-10

Legal Events

Date

Code

Title

Description

1995-05-31

MM3A

Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19940930

Publication	Publication Date	Title
PT72796B (fr)	1982-03-30	Dispositif accione par osmose
JPS5793065A (en)	1982-06-09	Permeation apparatus having hydrogel drive member
ATE280317T1 (de)	2004-11-15	Abgabevorrichtung für additive
ATE214898T1 (de)	2002-04-15	Blutbevorratungsverfahren
NO964264D0 (no)	1996-10-08	Osmotisk system for avgivelse av fluidsensitivt somatotropin til bovine dyr
SE8401185D0 (sv)	1984-03-02	Osmotiskt system med omedelbar lekemedelstillgenglighet
GB1509564A (en)	1978-05-04	Emitter apparatus for dispensing fluid
UA7225A1 (uk)	1995-06-30	Дозуючий пристрій, розташований у колпачку аерозольної ємкості
ES2194124T3 (es)	2003-11-16	Dispositivo para liberar un fluido dentro de un liquido en un contenedor.
AR246488A1 (es)	1994-08-31	Dispositivo dispensador para sustancias.
ES2134908T3 (es)	1999-10-16	Difusor con brida y retenedor de camara de aire para recipiente a presion.
DE69919854D1 (de)	2004-10-07	Ausgabevorrichtung
EP0704229A3 (de)	1997-02-05	Verfahren und Vorrichtung zum impulsförmigen Austragen einer Flüssigkeit, insbesondere eines Feuerlöschmittels
IT1133084B (it)	1986-07-09	Erogatore di agente attivo mediante diffusione particolarmente tavoletta medicinale a cessione graduale